<?xml version="1.0" encoding="UTF-8"?>
<rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"><channel rdf:about="http://onlinelibrary.wiley.com/rss/journal/10.1002/(ISSN)1934-6638" xmlns="http://purl.org/rss/1.0/"><title>Cancer Cytopathology</title><description> Wiley Online Library : Cancer Cytopathology</description><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2F%28ISSN%291934-6638</link><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc</dc:publisher><dc:language xmlns:dc="http://purl.org/dc/elements/1.1/">en</dc:language><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/">Copyright © 2013 American Cancer Society</dc:rights><prism:issn xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">1934-662X</prism:issn><prism:eIssn xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">1934-6638</prism:eIssn><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-06-01T00:00:00-05:00</dc:date><prism:coverDisplayDate xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">June 2013</prism:coverDisplayDate><prism:volume xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">121</prism:volume><prism:number xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">6</prism:number><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">277</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">338</prism:endingPage><image rdf:resource="http://onlinelibrary.wiley.com/store/10.1002/cncy.v121.6/asset/cover.gif?v=1&amp;s=59bb03a6539c8f75de4eaf3d14dd9925d3220f79"/><items><rdf:Seq><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21321"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21322"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21307"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21305"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21311"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21312"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21308"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21299"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21298"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21310"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21302"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21309"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21303"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21301"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21300"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21297"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21292"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21291"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21290"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21286"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21278"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21288"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21287"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21285"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21269"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21274"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21283"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21281"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21279"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21276"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21280"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21272"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21273"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21262"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21318"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21270"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21258"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21259"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21260"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21264"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21263"/></rdf:Seq></items></channel><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21321" xmlns="http://purl.org/rss/1.0/"><title>Epidermal growth factor receptor in lung cancer: The amazing interplay of molecular and cytology</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21321</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Epidermal growth factor receptor in lung cancer: The amazing interplay of molecular and cytology</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Michael O. Idowu</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-06-18T14:47:14.033381-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/cncy.21321</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/cncy.21321</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21321</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Editorial</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<div class="para" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib" xmlns="http://www.w3.org/1999/xhtml"><p>Cytology is increasingly playing a vital role in epidermal growth factor receptor and other molecular testing. Familiarity by cytopathologists with preanalytic, analytic, and postanalytic quality issues to ensure accurate and reproducible test results is critical. See also pages 000-000.</p></div>
]]></content:encoded><description>
Cytology is increasingly playing a vital role in epidermal growth factor receptor and other molecular testing. Familiarity by cytopathologists with preanalytic, analytic, and postanalytic quality issues to ensure accurate and reproducible test results is critical. See also pages 000-000.
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21322" xmlns="http://purl.org/rss/1.0/"><title>EGFR mutations detected on cytology samples by a centralized laboratory reliably predict response to gefitinib in non–small cell lung carcinoma patients</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21322</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">EGFR mutations detected on cytology samples by a centralized laboratory reliably predict response to gefitinib in non–small cell lung carcinoma patients</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Umberto Malapelle, Claudio Bellevicine, Caterina De Luca, Maria Salatiello, Alfonso De Stefano, Danilo Rocco, Nicla de Rosa, Fabiana Vitiello, Stefania Russo, Francesco Pepe, Antonino Iaccarino, Pietro Micheli, Alfonso Illiano, Chiara Carlomagno, Franco Vito Piantedosi, Giancarlo Troncone</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-06-18T14:47:08.580346-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/cncy.21322</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/cncy.21322</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21322</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<div class="section" id="cncy21322-sec-0001" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib" xmlns="http://www.w3.org/1999/xhtml"><h4>BACKGROUND</h4><div class="para"><p>Epidermal growth factor receptor (EGFR) mutations are reliably detected by referral laboratories, even if most lung cancer cytology specimens sent to such laboratories contain very few cells. However, EGFR mutations may be distributed heterogeneously within tumors, thereby raising concerns that mutations detected on cytology are not representative of the entire tumor and, thus, are less reliable in predicting response to tyrosine kinase inhibitor (TKI) treatment than mutations detected on histology. To address this issue, the authors reviewed their clinical practice archives and compared the outcome of TKI treatment among patients who were selected by cytology versus patients who were selected by histology.</p></div></div>
<div class="section" id="cncy21322-sec-0002" xmlns="http://www.w3.org/1999/xhtml"><h4>METHODS</h4><div class="para"><p>From July 2010 to July 2012, 364 cytology samples and 318 histology samples were received. Exon 19 deletions and the L858R point mutation in exon 21, detected by fragment assay and TaqMan assay, respectively, were confirmed by direct sequencing; discrepancies were resolved by cloning polymerase chain reaction products. The response rate (RR) and progression-free survival (PFS) at 12 months (range, 3-34 months) were evaluable in 13 EGFR-mutated patients who were selected for treatment by cytology and 13 patients who were selected by histology.</p></div></div>
<div class="section" id="cncy21322-sec-0003" xmlns="http://www.w3.org/1999/xhtml"><h4>RESULTS</h4><div class="para"><p>The mutation rate was similar in histology samples (8.5%) and cytology samples (8.8%). The RR (54%) and PFS (9.2 months) were similar in histologically selected patients and cytologically selected patients (RR, 62%; PFS, 8.6 months; P = .88). The disease control rate (responsive plus stable disease) was 92% in histologically selected patients and 100% in cytologically selected patients.</p></div></div>
<div class="section" id="cncy21322-sec-0004" xmlns="http://www.w3.org/1999/xhtml"><h4>CONCLUSIONS</h4><div class="para"><p>EGFR mutations detected on cytology specimens by a centralized laboratory can predict TKI treatment response equally well as mutations identified on histology samples. <b><em>Cancer (Cancer Cytopathol)</em> 2013</b>. © <em>2013 American Cancer Society</em>.</p></div></div>
]]></content:encoded><description>

BACKGROUND
Epidermal growth factor receptor (EGFR) mutations are reliably detected by referral laboratories, even if most lung cancer cytology specimens sent to such laboratories contain very few cells. However, EGFR mutations may be distributed heterogeneously within tumors, thereby raising concerns that mutations detected on cytology are not representative of the entire tumor and, thus, are less reliable in predicting response to tyrosine kinase inhibitor (TKI) treatment than mutations detected on histology. To address this issue, the authors reviewed their clinical practice archives and compared the outcome of TKI treatment among patients who were selected by cytology versus patients who were selected by histology.


METHODS
From July 2010 to July 2012, 364 cytology samples and 318 histology samples were received. Exon 19 deletions and the L858R point mutation in exon 21, detected by fragment assay and TaqMan assay, respectively, were confirmed by direct sequencing; discrepancies were resolved by cloning polymerase chain reaction products. The response rate (RR) and progression-free survival (PFS) at 12 months (range, 3-34 months) were evaluable in 13 EGFR-mutated patients who were selected for treatment by cytology and 13 patients who were selected by histology.


RESULTS
The mutation rate was similar in histology samples (8.5%) and cytology samples (8.8%). The RR (54%) and PFS (9.2 months) were similar in histologically selected patients and cytologically selected patients (RR, 62%; PFS, 8.6 months; P = .88). The disease control rate (responsive plus stable disease) was 92% in histologically selected patients and 100% in cytologically selected patients.


CONCLUSIONS
EGFR mutations detected on cytology specimens by a centralized laboratory can predict TKI treatment response equally well as mutations identified on histology samples. Cancer (Cancer Cytopathol) 2013. © 2013 American Cancer Society.

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21307" xmlns="http://purl.org/rss/1.0/"><title>Can a gene-expression classifier with high negative predictive value solve the indeterminate thyroid fine-needle aspiration dilemma?</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21307</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Can a gene-expression classifier with high negative predictive value solve the indeterminate thyroid fine-needle aspiration dilemma?</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Esther Diana Rossi, Luigi Maria Larocca, Guido Fadda</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-06-13T11:10:27.745658-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/cncy.21307</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/cncy.21307</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21307</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Correspondence</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[]]></content:encoded><description/></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21305" xmlns="http://purl.org/rss/1.0/"><title>Reply to can a gene-expression classifier with high negative predictive value solve the indeterminate thyroid fine-needle aspiration dilemma?</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21305</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Reply to can a gene-expression classifier with high negative predictive value solve the indeterminate thyroid fine-needle aspiration dilemma?</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">William C. Faquin</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-06-13T11:09:41.888572-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/cncy.21305</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/cncy.21305</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21305</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Reply to Correspondence</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[]]></content:encoded><description/></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21311" xmlns="http://purl.org/rss/1.0/"><title>Kaposi sarcoma herpesvirus/human herpesvirus-8–negative effusion-based lymphoma: Report of 3 cases and review of the literature</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21311</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Kaposi sarcoma herpesvirus/human herpesvirus-8–negative effusion-based lymphoma: Report of 3 cases and review of the literature</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Jingnan Xiao, Suzanne M. Selvaggi, Catherine P. Leith, Sean A Fitzgerald, Jimmie Stewart</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-06-13T11:09:30.692987-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/cncy.21311</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/cncy.21311</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21311</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<div class="section" id="cncy21311-sec-0001" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib" xmlns="http://www.w3.org/1999/xhtml"><h4>BACKGROUND</h4><div class="para"><p>Primary effusion lymphoma (PEL) is a rare subtype of large B-cell lymphoma that arises in body cavities without detectable tumor masses. PEL is universally associated with Kaposi sarcoma herpesvirus (KSHV)/human herpesvirus-8 (HHV8). Despite overlapping features, KSHV/HHV8-negative effusion-based lymphoma is a distinct entity from PEL. To date, 52 cases have been reported. The authors report 3 additional cases received in their laboratory from 2007 to 2012.</p></div></div>
<div class="section" id="cncy21311-sec-0002" xmlns="http://www.w3.org/1999/xhtml"><h4>METHODS</h4><div class="para"><p>Clinical data, cytomorphologic features, and immunophenotypic features of the 3 cases were described and compared with those reported in the literature.</p></div></div>
<div class="section" id="cncy21311-sec-0003" xmlns="http://www.w3.org/1999/xhtml"><h4>RESULTS</h4><div class="para"><p>The cells in HHV8-negative effusion lymphoma commonly revealed large cell, immunoblastic morphology and B-cell immunophenotype. The 3 cases demonstrated cytomorphologic and immunophenotypic variability. Cytomorphologically, 1 case contained large, highly atypical cells with a moderate amount of cytoplasm, round nucleus, coarsely granular chromatin, and a single macronucleolus. The other 2 cases had medium to large atypical cells with high nuclear-to-cytoplasmic ratios, slightly irregular to cleaved nuclei, and multiple conspicuous nucleoli. One case had a null phenotype with aberrant cytokeratin expression. B-cell phenotype was established by clonal immunoglobulin heavy-chain rearrangement using polymerase chain reaction, whereas the other 2 cases demonstrated a B-cell phenotype by flow cytometry and immunohistochemical staining. All 3 cases were negative for both HHV8 and Epstein-Barr virus.</p></div></div>
<div class="section" id="cncy21311-sec-0004" xmlns="http://www.w3.org/1999/xhtml"><h4>CONCLUSIONS</h4><div class="para"><p>HHV8-negative effusion lymphoma exhibits clinical, cytomorphologic, and immunophenotypic variability. Cases with a null-phenotype can be particularly challenging. When effusion lymphoma is suspected, ancillary tests are helpful. Moreover, HHV8 detection is critical in differentiating PEL and HHV8-negative effusion lymphoma, because they have overlapping features yet different prognoses. <b><em>Cancer (Cancer Cytopathol)</em> 2013</b>. © <em>2013 American Cancer Society</em>.</p></div></div>
]]></content:encoded><description>

BACKGROUND
Primary effusion lymphoma (PEL) is a rare subtype of large B-cell lymphoma that arises in body cavities without detectable tumor masses. PEL is universally associated with Kaposi sarcoma herpesvirus (KSHV)/human herpesvirus-8 (HHV8). Despite overlapping features, KSHV/HHV8-negative effusion-based lymphoma is a distinct entity from PEL. To date, 52 cases have been reported. The authors report 3 additional cases received in their laboratory from 2007 to 2012.


METHODS
Clinical data, cytomorphologic features, and immunophenotypic features of the 3 cases were described and compared with those reported in the literature.


RESULTS
The cells in HHV8-negative effusion lymphoma commonly revealed large cell, immunoblastic morphology and B-cell immunophenotype. The 3 cases demonstrated cytomorphologic and immunophenotypic variability. Cytomorphologically, 1 case contained large, highly atypical cells with a moderate amount of cytoplasm, round nucleus, coarsely granular chromatin, and a single macronucleolus. The other 2 cases had medium to large atypical cells with high nuclear-to-cytoplasmic ratios, slightly irregular to cleaved nuclei, and multiple conspicuous nucleoli. One case had a null phenotype with aberrant cytokeratin expression. B-cell phenotype was established by clonal immunoglobulin heavy-chain rearrangement using polymerase chain reaction, whereas the other 2 cases demonstrated a B-cell phenotype by flow cytometry and immunohistochemical staining. All 3 cases were negative for both HHV8 and Epstein-Barr virus.


CONCLUSIONS
HHV8-negative effusion lymphoma exhibits clinical, cytomorphologic, and immunophenotypic variability. Cases with a null-phenotype can be particularly challenging. When effusion lymphoma is suspected, ancillary tests are helpful. Moreover, HHV8 detection is critical in differentiating PEL and HHV8-negative effusion lymphoma, because they have overlapping features yet different prognoses. Cancer (Cancer Cytopathol) 2013. © 2013 American Cancer Society.

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21312" xmlns="http://purl.org/rss/1.0/"><title>High-grade squamous intraepithelial lesion in women aged &lt;30 years has a prevalence pattern resembling low-grade squamous intraepithelial lesion</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21312</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">High-grade squamous intraepithelial lesion in women aged &lt;30 years has a prevalence pattern resembling low-grade squamous intraepithelial lesion</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Diama B. Vale, Maria C. Westin, Luiz C. Zeferino</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-06-13T11:08:17.604123-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/cncy.21312</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/cncy.21312</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21312</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<div class="section" id="cncy21312-sec-0001" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib" xmlns="http://www.w3.org/1999/xhtml"><h4>BACKGROUND</h4><div class="para"><p>Cervical cytology is the cervical cancer screening test for women aged &lt;30 years because of the low specificity of human papillomavirus tests in this age group. The Bethesda System classifies cervical intraepithelial neoplasia grade 2 (CIN 2) and grade 3 (CIN 3) as high-grade intraepithelial lesions (HSIL). In this study, the authors subclassified cytologic HSIL as suggestive of CIN 2 (HSIL-CIN 2) or CIN 3 (HSIL-CIN 3) and evaluated whether there was a correlation between these findings and age for screened and unscreened women.</p></div></div>
<div class="section" id="cncy21312-sec-0002" xmlns="http://www.w3.org/1999/xhtml"><h4>METHODS</h4><div class="para"><p>The study included 2,002,472 cervical smears collected from women who had at least 1 previous test (screened) and 217,826 previously untested women (unscreened). The laboratory has been using the Bethesda System since 1998 with the subcategorization of HSIL-CIN 2 and HSIL-CIN 3.</p></div></div>
<div class="section" id="cncy21312-sec-0003" xmlns="http://www.w3.org/1999/xhtml"><h4>RESULTS</h4><div class="para"><p>For unscreened women, the prevalence of low-grade intraepithelial lesion (LSIL) and HSIL-CIN 2 decreased with age, whereas the prevalence of HSIL-CIN 3 increased. The prevalence of HSIL-CIN 2 was greater than that of HSIL-CIN 3 for women up to age 29 years (prevalence ratio [PR], 4.73; 95% confidence interval [CI],  3.90-5.75) and lower for the groups ages 30 to 49 years (PR, 0.66; 95% CI, 0.50-0.87) and ≥50 years (PR, 0.21; 95% CI, 0.12-0.36). For screened women, the prevalence of HSIL-CIN 2 also was greater in the group aged ≤29 years (PR, 2.72; 95% CI, 2.49-2.97).</p></div></div>
<div class="section" id="cncy21312-sec-0004" xmlns="http://www.w3.org/1999/xhtml"><h4>CONCLUSIONS</h4><div class="para"><p>The prevalence pattern of HSIL suggestive of CIN 2 resembled the pattern observed in LSIL and was more prevalent than HSIL suggestive of CIN 3 in younger women. The impact of screening was less evident when HSIL was suggestive of CIN 2. A conservative approach for younger women who have HSIL is important for management guidance. <b><em>Cancer (Cancer Cytopathol)</em> 2013</b>. © <em>2013 American Cancer Society</em>.</p></div></div>
]]></content:encoded><description>

BACKGROUND
Cervical cytology is the cervical cancer screening test for women aged &lt;30 years because of the low specificity of human papillomavirus tests in this age group. The Bethesda System classifies cervical intraepithelial neoplasia grade 2 (CIN 2) and grade 3 (CIN 3) as high-grade intraepithelial lesions (HSIL). In this study, the authors subclassified cytologic HSIL as suggestive of CIN 2 (HSIL-CIN 2) or CIN 3 (HSIL-CIN 3) and evaluated whether there was a correlation between these findings and age for screened and unscreened women.


METHODS
The study included 2,002,472 cervical smears collected from women who had at least 1 previous test (screened) and 217,826 previously untested women (unscreened). The laboratory has been using the Bethesda System since 1998 with the subcategorization of HSIL-CIN 2 and HSIL-CIN 3.


RESULTS
For unscreened women, the prevalence of low-grade intraepithelial lesion (LSIL) and HSIL-CIN 2 decreased with age, whereas the prevalence of HSIL-CIN 3 increased. The prevalence of HSIL-CIN 2 was greater than that of HSIL-CIN 3 for women up to age 29 years (prevalence ratio [PR], 4.73; 95% confidence interval [CI],  3.90-5.75) and lower for the groups ages 30 to 49 years (PR, 0.66; 95% CI, 0.50-0.87) and ≥50 years (PR, 0.21; 95% CI, 0.12-0.36). For screened women, the prevalence of HSIL-CIN 2 also was greater in the group aged ≤29 years (PR, 2.72; 95% CI, 2.49-2.97).


CONCLUSIONS
The prevalence pattern of HSIL suggestive of CIN 2 resembled the pattern observed in LSIL and was more prevalent than HSIL suggestive of CIN 3 in younger women. The impact of screening was less evident when HSIL was suggestive of CIN 2. A conservative approach for younger women who have HSIL is important for management guidance. Cancer (Cancer Cytopathol) 2013. © 2013 American Cancer Society.

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21308" xmlns="http://purl.org/rss/1.0/"><title>Breast fine-needle aspiration cytology performance in the high-risk screening population</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21308</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Breast fine-needle aspiration cytology performance in the high-risk screening population</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Radka D. Georgieva, Inge M. Obdeijn, Agnes Jager, Maartje J. Hooning, Madeleine M. A. Tilanus-Linthorst, Carolien H. M. van Deurzen</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-05-29T11:44:09.397177-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/cncy.21308</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/cncy.21308</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21308</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<div class="section" id="cncy21308-sec-0001" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib" xmlns="http://www.w3.org/1999/xhtml"><h4>BACKGROUND</h4><div class="para"><p>The diagnosis of breast lesions is usually confirmed by fine-needle aspiration cytology (FNAC) or histological biopsy. Although there is increasing literature regarding the advantages and limitations of both modalities, there is no literature regarding the accuracy of these modalities for diagnosing breast lesions in high-risk patients, who usually have lesions detected by screening. The objective of the current study was to evaluate diagnostic performance indices of FNAC in breast cancer susceptibility gene (BRCA) mutation carriers.</p></div></div>
<div class="section" id="cncy21308-sec-0002" xmlns="http://www.w3.org/1999/xhtml"><h4>METHODS</h4><div class="para"><p>BRCA1/BRCA2 mutation carriers who underwent FNAC were selected from the database of the Rotterdam Family Cancer Clinic. FNAC accuracy parameters were calculated by taking the outcome of a subsequent histological diagnosis or clinical follow-up as reference standard.</p></div></div>
<div class="section" id="cncy21308-sec-0003" xmlns="http://www.w3.org/1999/xhtml"><h4>RESULTS</h4><div class="para"><p>In total, 320 FNACs were obtained, and FNAC examination was followed by histological examination in 150 patients. The rate of insufficient material was 25.6%. Sensitivity was 92.3%, specificity 96.3%. The false-positive rate was 3.7%, the false-negative rate was 7.7%, and accuracy was 94.7%. A substantial proportion of patients (35%) with malignant FNAC results underwent histological biopsy upfront surgical resection. Small lesion size (≤1 cm) and nonpalpability of the breast lesion were associated with decreased FNAC accuracy. In 113 patients who had a benign FNAC outcome without histological follow-up, no malignancies were detected during clinical or radiologic surveillance (median follow-up 84 months).</p></div></div>
<div class="section" id="cncy21308-sec-0004" xmlns="http://www.w3.org/1999/xhtml"><h4>CONCLUSIONS</h4><div class="para"><p>There is a role for FNAC in diagnosing breast lesions of BRCA1/BRCA2 mutation carriers, ie, to confirm a radiological (probably) benign lesion. However, despite the high overall sensitivity of FNAC, the authors recommend histological biopsy as the preferred diagnostic method for high-risk patients who have small or nonpalpable lesions. Cancer (Cancer Cytopathol) 2013. © 2013 American Cancer Society.</p></div></div>
]]></content:encoded><description>

BACKGROUND
The diagnosis of breast lesions is usually confirmed by fine-needle aspiration cytology (FNAC) or histological biopsy. Although there is increasing literature regarding the advantages and limitations of both modalities, there is no literature regarding the accuracy of these modalities for diagnosing breast lesions in high-risk patients, who usually have lesions detected by screening. The objective of the current study was to evaluate diagnostic performance indices of FNAC in breast cancer susceptibility gene (BRCA) mutation carriers.


METHODS
BRCA1/BRCA2 mutation carriers who underwent FNAC were selected from the database of the Rotterdam Family Cancer Clinic. FNAC accuracy parameters were calculated by taking the outcome of a subsequent histological diagnosis or clinical follow-up as reference standard.


RESULTS
In total, 320 FNACs were obtained, and FNAC examination was followed by histological examination in 150 patients. The rate of insufficient material was 25.6%. Sensitivity was 92.3%, specificity 96.3%. The false-positive rate was 3.7%, the false-negative rate was 7.7%, and accuracy was 94.7%. A substantial proportion of patients (35%) with malignant FNAC results underwent histological biopsy upfront surgical resection. Small lesion size (≤1 cm) and nonpalpability of the breast lesion were associated with decreased FNAC accuracy. In 113 patients who had a benign FNAC outcome without histological follow-up, no malignancies were detected during clinical or radiologic surveillance (median follow-up 84 months).


CONCLUSIONS
There is a role for FNAC in diagnosing breast lesions of BRCA1/BRCA2 mutation carriers, ie, to confirm a radiological (probably) benign lesion. However, despite the high overall sensitivity of FNAC, the authors recommend histological biopsy as the preferred diagnostic method for high-risk patients who have small or nonpalpable lesions. Cancer (Cancer Cytopathol) 2013. © 2013 American Cancer Society.

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21299" xmlns="http://purl.org/rss/1.0/"><title>False-negative rate of endoscopic ultrasound-guided fine-needle aspiration for pancreatic solid and cystic lesions with matched surgical resections as the gold standard</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21299</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">False-negative rate of endoscopic ultrasound-guided fine-needle aspiration for pancreatic solid and cystic lesions with matched surgical resections as the gold standard</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Kirsten M. W. Woolf, Hua Liang, Zachary J. Sletten, Donna K. Russell, Thomas A. Bonfiglio, Zhongren Zhou</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-05-15T08:21:49.764874-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/cncy.21299</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/cncy.21299</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21299</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<div class="section" id="cncy21299-sec-0001" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib" xmlns="http://www.w3.org/1999/xhtml"><h4>BACKGROUND</h4><div class="para"><p>The diagnosis of pancreatic tumors is often complicated because of sampling and interpretive challenges. The current study was performed to determine the rates, types, and causes of diagnostic discrepancies.</p></div></div>
<div class="section" id="cncy21299-sec-0002" xmlns="http://www.w3.org/1999/xhtml"><h4>METHODS</h4><div class="para"><p>The authors retrospectively reviewed cytology cases from 2004 to 2010 using matched surgical resection cases as the gold standard.</p></div></div>
<div class="section" id="cncy21299-sec-0003" xmlns="http://www.w3.org/1999/xhtml"><h4>RESULTS</h4><div class="para"><p>A total of 733 cases were divided into 3 categories: 1) positive or suspicious (290 cases); 2) negative or atypical (403 cases); and 3) unsatisfactory (40 cases). Of these cases, 101 fine-needle aspiration (FNA) cases had matched surgical resections including 58 positive diagnoses, 39 negative diagnoses, and 4 unsatisfactory diagnoses. All 19 discrepant cases represented false-negative diagnoses without any false-positive cases noted, which included 2 cases with interpretive errors (10%) and 17 cases with sampling errors (90%). All matched cytology cases were divided into 5 subgroups based on the type of lesion or type of error and were analyzed for sensitivity and specificity. The sampling error rate in cystic lesions (8 of 24; 33%) was significantly higher than that in solid lesions (9 of 73; 12%). The false-negative rate in the interpretive error group (3%) was significantly lower than that in the sampling error group (23%).</p></div></div>
<div class="section" id="cncy21299-sec-0004" xmlns="http://www.w3.org/1999/xhtml"><h4>CONCLUSIONS</h4><div class="para"><p>The results of the current study confirm that pancreatic endoscopic ultrasound-guided FNA diagnosis has a very low false-positive rate but a relatively high false-negative rate using matched surgical resections as the gold standard. The major cause of a false-negative cytology diagnosis is sampling error and the rate of sampling error in cystic lesions is significantly higher than that in solid lesions. <b><em>Cancer (Cancer Cytopathol)</em> 2013</b>. © <em>2013 American Cancer Society</em>.</p></div></div>
]]></content:encoded><description>

BACKGROUND
The diagnosis of pancreatic tumors is often complicated because of sampling and interpretive challenges. The current study was performed to determine the rates, types, and causes of diagnostic discrepancies.


METHODS
The authors retrospectively reviewed cytology cases from 2004 to 2010 using matched surgical resection cases as the gold standard.


RESULTS
A total of 733 cases were divided into 3 categories: 1) positive or suspicious (290 cases); 2) negative or atypical (403 cases); and 3) unsatisfactory (40 cases). Of these cases, 101 fine-needle aspiration (FNA) cases had matched surgical resections including 58 positive diagnoses, 39 negative diagnoses, and 4 unsatisfactory diagnoses. All 19 discrepant cases represented false-negative diagnoses without any false-positive cases noted, which included 2 cases with interpretive errors (10%) and 17 cases with sampling errors (90%). All matched cytology cases were divided into 5 subgroups based on the type of lesion or type of error and were analyzed for sensitivity and specificity. The sampling error rate in cystic lesions (8 of 24; 33%) was significantly higher than that in solid lesions (9 of 73; 12%). The false-negative rate in the interpretive error group (3%) was significantly lower than that in the sampling error group (23%).


CONCLUSIONS
The results of the current study confirm that pancreatic endoscopic ultrasound-guided FNA diagnosis has a very low false-positive rate but a relatively high false-negative rate using matched surgical resections as the gold standard. The major cause of a false-negative cytology diagnosis is sampling error and the rate of sampling error in cystic lesions is significantly higher than that in solid lesions. Cancer (Cancer Cytopathol) 2013. © 2013 American Cancer Society.

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21298" xmlns="http://purl.org/rss/1.0/"><title>Fine-needle aspiration of histoplasmosis in the era of endoscopic ultrasound and endobronchial ultrasound</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21298</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Fine-needle aspiration of histoplasmosis in the era of endoscopic ultrasound and endobronchial ultrasound</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Michael P. Gailey, J. Stacey Klutts, Chris S. Jensen</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-05-15T08:20:33.211661-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/cncy.21298</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/cncy.21298</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21298</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<div class="section" id="cncy21298-sec-0001" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib" xmlns="http://www.w3.org/1999/xhtml"><h4>BACKGROUND</h4><div class="para"><p>Histoplasmosis has a textbook cytologic description with numerous intracellular organisms that are readily apparent on routine stains. This is based on series and reports describing histoplasmosis in immunosuppressed patients with disseminated disease. With the advent of ultrasound-guided (US) fine-needle aspiration (FNA) techniques, a marked increase in the cytologic diagnosis of histoplasmosis in immunocompetent patients is noted.</p></div></div>
<div class="section" id="cncy21298-sec-0002" xmlns="http://www.w3.org/1999/xhtml"><h4>METHODS</h4><div class="para"><p>A search identified all cytology cases diagnosed with <em>Histoplasma</em> within the past 10 years. Cases were reviewed, along with patient demographic, clinical, and laboratory data.</p></div></div>
<div class="section" id="cncy21298-sec-0003" xmlns="http://www.w3.org/1999/xhtml"><h4>RESULTS</h4><div class="para"><p>A total of 40 FNA cases of histoplasmosis were identified. Patients ranged in age from 15 years to 86 years. There were 23 female patients and 17 male patients; 37 were immunocompetent and 3 were immunosuppressed. Sixteen patients were being staged for primary tumors of other sites; others presented with primary pulmonary symptoms or histoplasmosis was noted incidentally. Specimens were composed of bland acellular necrosis, most commonly with granulomas (77.5%); only rare intracellular organisms were present on routine stains, and variable extracellular organisms were noted on Grocott methenamine silver stain (GMS) stain. GMS stain on direct smears was found to be more sensitive than cell block. Laboratory studies for urine antigen, yeast, and mycelial antibody (by compliment fixation), serum antibody (by immunodiffusion), and culture were positive in 11.8%, 59.1%, 4.5%, 47.6%, and 3.4% of cases, respectively.</p></div></div>
<div class="section" id="cncy21298-sec-0004" xmlns="http://www.w3.org/1999/xhtml"><h4>CONCLUSIONS</h4><div class="para"><p>In an endemic region, histoplasmosis presents more commonly in immunocompetent patients as localized fibrocaseous disease on FNA and is often identified by high-resolution imaging. FNA is increasingly used in the diagnosis because of endoscopic ultrasound and endobronchial ultrasound. GMS stain on direct smears is more sensitive than cell block. In general, laboratory tests have low sensitivity in this patient population. <b><em>Cancer (Cancer Cytopathol)</em> 2013</b>. © <em>2013 American Cancer Society</em>.</p></div></div>
]]></content:encoded><description>

BACKGROUND
Histoplasmosis has a textbook cytologic description with numerous intracellular organisms that are readily apparent on routine stains. This is based on series and reports describing histoplasmosis in immunosuppressed patients with disseminated disease. With the advent of ultrasound-guided (US) fine-needle aspiration (FNA) techniques, a marked increase in the cytologic diagnosis of histoplasmosis in immunocompetent patients is noted.


METHODS
A search identified all cytology cases diagnosed with Histoplasma within the past 10 years. Cases were reviewed, along with patient demographic, clinical, and laboratory data.


RESULTS
A total of 40 FNA cases of histoplasmosis were identified. Patients ranged in age from 15 years to 86 years. There were 23 female patients and 17 male patients; 37 were immunocompetent and 3 were immunosuppressed. Sixteen patients were being staged for primary tumors of other sites; others presented with primary pulmonary symptoms or histoplasmosis was noted incidentally. Specimens were composed of bland acellular necrosis, most commonly with granulomas (77.5%); only rare intracellular organisms were present on routine stains, and variable extracellular organisms were noted on Grocott methenamine silver stain (GMS) stain. GMS stain on direct smears was found to be more sensitive than cell block. Laboratory studies for urine antigen, yeast, and mycelial antibody (by compliment fixation), serum antibody (by immunodiffusion), and culture were positive in 11.8%, 59.1%, 4.5%, 47.6%, and 3.4% of cases, respectively.


CONCLUSIONS
In an endemic region, histoplasmosis presents more commonly in immunocompetent patients as localized fibrocaseous disease on FNA and is often identified by high-resolution imaging. FNA is increasingly used in the diagnosis because of endoscopic ultrasound and endobronchial ultrasound. GMS stain on direct smears is more sensitive than cell block. In general, laboratory tests have low sensitivity in this patient population. Cancer (Cancer Cytopathol) 2013. © 2013 American Cancer Society.

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21310" xmlns="http://purl.org/rss/1.0/"><title>Immunohistochemical analysis of E-cadherin and zeste homolog 2 expression in endoscopic ultrasound-guided fine-needle aspiration of pancreatic adenocarcinoma</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21310</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Immunohistochemical analysis of E-cadherin and zeste homolog 2 expression in endoscopic ultrasound-guided fine-needle aspiration of pancreatic adenocarcinoma</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Ling Gao, Tatjana Antic, Elizabeth Hyjek, Can Gong, Jeffrey Mueller, Irving Waxman, Richard M. DeMay, Ward Reeves</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-05-14T10:16:36.808969-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/cncy.21310</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/cncy.21310</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21310</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<div class="section" id="cncy21310-sec-0001" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib" xmlns="http://www.w3.org/1999/xhtml"><h4>BACKGROUND</h4><div class="para"><p>Recent studies have demonstrated that partial or complete loss of E-cadherin (EC) and nuclear accumulation of zeste homolog 2 (EZH2) are hallmarks of poorly differentiated pancreatic adenocarcinoma (PAC). Depletion of EZH2 sensitizes cancer cells to chemotherapy in vitro. The objective of this study was to determine EC and EZH2 expression by immunohistochemistry (IHC) in samples obtained by endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) as potential biomarkers for treatment and disease prognosis.</p></div></div>
<div class="section" id="cncy21310-sec-0002" xmlns="http://www.w3.org/1999/xhtml"><h4>METHODS</h4><div class="para"><p>Thirty-eight EUS-FNA samples from patients with a PAC diagnosis were analyzed by IHC for EC and EZH2 expression. Seven corresponding surgical resection specimens were included in the study. The intensity of EZH2 and EC expression in PAC and in normal gastrointestinal pick-ups (internal positive control) was scored by using a 4-tier grading system.</p></div></div>
<div class="section" id="cncy21310-sec-0003" xmlns="http://www.w3.org/1999/xhtml"><h4>RESULTS</h4><div class="para"><p>EC demonstrated a focal, weak-to-moderate decrease in 24 PAC samples. Complete loss of EC expression was observed in the poorly differentiated areas represented by single tumor cells. The average staining intensity of EC in samples of poorly differentiated PAC was significantly lower than that of moderately differentiated PAC samples (P = .0005). EZH2 was variably positive in 31 of 38 PAC samples. The average staining intensity of EZH2 in moderately and poorly differentiated PACs did not differ significantly (P = .81).</p></div></div>
<div class="section" id="cncy21310-sec-0004" xmlns="http://www.w3.org/1999/xhtml"><h4>CONCLUSIONS</h4><div class="para"><p>EC and EZH2 expression was determined reliably by IHC on paraffin sections of EUS-FNA cell block specimens. The current results were consistent with prior reports indicating a decrease or loss of EC expression in poorly differentiated PAC. However, EZH2 expression did not always correlate inversely with EC expression and was more heterogeneous. <b><em>Cancer (Cancer Cytopathol)</em> 2013</b>. © <em>2013 American Cancer Society</em>.</p></div></div>
]]></content:encoded><description>

BACKGROUND
Recent studies have demonstrated that partial or complete loss of E-cadherin (EC) and nuclear accumulation of zeste homolog 2 (EZH2) are hallmarks of poorly differentiated pancreatic adenocarcinoma (PAC). Depletion of EZH2 sensitizes cancer cells to chemotherapy in vitro. The objective of this study was to determine EC and EZH2 expression by immunohistochemistry (IHC) in samples obtained by endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) as potential biomarkers for treatment and disease prognosis.


METHODS
Thirty-eight EUS-FNA samples from patients with a PAC diagnosis were analyzed by IHC for EC and EZH2 expression. Seven corresponding surgical resection specimens were included in the study. The intensity of EZH2 and EC expression in PAC and in normal gastrointestinal pick-ups (internal positive control) was scored by using a 4-tier grading system.


RESULTS
EC demonstrated a focal, weak-to-moderate decrease in 24 PAC samples. Complete loss of EC expression was observed in the poorly differentiated areas represented by single tumor cells. The average staining intensity of EC in samples of poorly differentiated PAC was significantly lower than that of moderately differentiated PAC samples (P = .0005). EZH2 was variably positive in 31 of 38 PAC samples. The average staining intensity of EZH2 in moderately and poorly differentiated PACs did not differ significantly (P = .81).


CONCLUSIONS
EC and EZH2 expression was determined reliably by IHC on paraffin sections of EUS-FNA cell block specimens. The current results were consistent with prior reports indicating a decrease or loss of EC expression in poorly differentiated PAC. However, EZH2 expression did not always correlate inversely with EC expression and was more heterogeneous. Cancer (Cancer Cytopathol) 2013. © 2013 American Cancer Society.

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21302" xmlns="http://purl.org/rss/1.0/"><title>Endosalpingiosis in peritoneal washings in women with benign gynecologic conditions</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21302</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Endosalpingiosis in peritoneal washings in women with benign gynecologic conditions</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Nour Sneige, Marilyn A. Dawlett, Teresa L. Kologinczak, Ming Guo</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-05-14T10:16:30.827206-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/cncy.21302</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/cncy.21302</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21302</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<div class="section" id="cncy21302-sec-0001" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib" xmlns="http://www.w3.org/1999/xhtml"><h4>BACKGROUND</h4><div class="para"><p>To better define the cytomorphologic spectrum of endosalpingiosis in peritoneal washings (PWs) and thereby facilitate their distinction from well differentiated serous carcinoma, the authors examined PWs from women who underwent surgery and pathologic staging of lesions other than Mullerian malignancies and correlated the findings with surgical specimens.</p></div></div>
<div class="section" id="cncy21302-sec-0002" xmlns="http://www.w3.org/1999/xhtml"><h4>METHODS</h4><div class="para"><p>This was a retrospective review of medical records and PW specimens from 100 consecutive patients who had PWs coded as both “endosalpingiosis” and “negative for carcinoma” between 2002 and 2012. Thirty-eight of these patients had no gynecologic malignancies. Specimens had been prepared using cytocentrifugation and were stained using the Papanicolaou method. The cytologic findings evaluated were cell arrangement, number of cell groups per case, cellular atypia, and psammoma bodies. Smears also were assessed for paired box-8 (PAX8) immunostaining. The authors compared patients' staging biopsy findings with the findings from a review of the PWs.</p></div></div>
<div class="section" id="cncy21302-sec-0003" xmlns="http://www.w3.org/1999/xhtml"><h4>RESULTS</h4><div class="para"><p>PW specimens from 35 of 38 patients (92%) exhibited classic endosalpingiosis features: tubular or small branching papillary structures, some with psammoma bodies. Specimens from the 3 remaining patients displayed nonclassic features consistent with dislodged fallopian tube epithelium or endometriosis. From 2 to 20 clusters per slide and from 4 to 50 groups per case were identified. In a few cases, some cell clusters exhibited up to moderate cytologic atypia. Surgical findings included endometriosis, endosalpingiosis, both endometriosis and endosalpingiosis (12 patients; 31.6%), and a variety of unrelated pelvic lesions. All cases were PAX8-positive, confirming their Mullerian origin.</p></div></div>
<div class="section" id="cncy21302-sec-0004" xmlns="http://www.w3.org/1999/xhtml"><h4>CONCLUSIONS</h4><div class="para"><p>Endosalpingiosis in PWs can be diagnostically challenging. Awareness of intraoperative techniques and correlation with surgical biopsy findings are necessary to avoid a misdiagnosis of malignancy. <b><em>Cancer (Cancer Cytopathol)</em> 2013</b>. © <em>2013 American Cancer Society</em>.</p></div></div>
]]></content:encoded><description>

BACKGROUND
To better define the cytomorphologic spectrum of endosalpingiosis in peritoneal washings (PWs) and thereby facilitate their distinction from well differentiated serous carcinoma, the authors examined PWs from women who underwent surgery and pathologic staging of lesions other than Mullerian malignancies and correlated the findings with surgical specimens.


METHODS
This was a retrospective review of medical records and PW specimens from 100 consecutive patients who had PWs coded as both “endosalpingiosis” and “negative for carcinoma” between 2002 and 2012. Thirty-eight of these patients had no gynecologic malignancies. Specimens had been prepared using cytocentrifugation and were stained using the Papanicolaou method. The cytologic findings evaluated were cell arrangement, number of cell groups per case, cellular atypia, and psammoma bodies. Smears also were assessed for paired box-8 (PAX8) immunostaining. The authors compared patients' staging biopsy findings with the findings from a review of the PWs.


RESULTS
PW specimens from 35 of 38 patients (92%) exhibited classic endosalpingiosis features: tubular or small branching papillary structures, some with psammoma bodies. Specimens from the 3 remaining patients displayed nonclassic features consistent with dislodged fallopian tube epithelium or endometriosis. From 2 to 20 clusters per slide and from 4 to 50 groups per case were identified. In a few cases, some cell clusters exhibited up to moderate cytologic atypia. Surgical findings included endometriosis, endosalpingiosis, both endometriosis and endosalpingiosis (12 patients; 31.6%), and a variety of unrelated pelvic lesions. All cases were PAX8-positive, confirming their Mullerian origin.


CONCLUSIONS
Endosalpingiosis in PWs can be diagnostically challenging. Awareness of intraoperative techniques and correlation with surgical biopsy findings are necessary to avoid a misdiagnosis of malignancy. Cancer (Cancer Cytopathol) 2013. © 2013 American Cancer Society.

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21309" xmlns="http://purl.org/rss/1.0/"><title>Effects of transitioning from conventional methods to liquid-based methods on unsatisfactory Papanicolaou tests</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21309</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Effects of transitioning from conventional methods to liquid-based methods on unsatisfactory Papanicolaou tests</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Christopher L. Owens, Dan Peterson, Aruna Kamineni, Diana S. M. Buist, Sheila Weinmann, Tyler R. Ross, Andrew E. Williams, Azadeh Stark, Kenneth F. Adams, Terry S. Field</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-05-08T10:05:30.284394-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/cncy.21309</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/cncy.21309</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21309</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<div class="section" id="cncy21309-sec-0001" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib" xmlns="http://www.w3.org/1999/xhtml"><h4>BACKGROUND</h4><div class="para"><p>Papanicolaou (Pap) testing has transitioned from conventional preparations (CPs) to liquid-based preparations (LBPs) because of the perceived superiority of LBPs. Many studies conclude that LBPs reduce unsatisfactory Pap tests; however, some believe that the evidence substantiating this claim is weak. The authors studied the effect of the transition from CPs to LBPs on the proportion of unsatisfactory Pap tests in 4 health care systems in the United States participating in the National Institutes of Health-funded Screening Effectiveness and Research in Community-Based Healthcare (SEARCH) project.</p></div></div>
<div class="section" id="cncy21309-sec-0002" xmlns="http://www.w3.org/1999/xhtml"><h4>METHODS</h4><div class="para"><p>The study cohort consisted of 548,174 women ages 21 to 65 years who had 1443,725 total Pap tests between 2000 and 2010. Segmented regression analysis was used to estimate the effect of adopting LBPs on the proportion of unsatisfactory Pap tests after adjusting for age.</p></div></div>
<div class="section" id="cncy21309-sec-0003" xmlns="http://www.w3.org/1999/xhtml"><h4>RESULTS</h4><div class="para"><p>Three sites that implemented SurePath LBP experienced significant reductions in unsatisfactory Pap tests (estimated effect: site 1, −2.46%; 95% confidence interval [CI], −1.47%, −3.45%; site 2, −1.78%; 95% CI, −1.54%, −2.02%; site 3, −8.25%; 95% CI, −7.33%, −9.17%). The fourth site that implemented ThinPrep LBP did not experience a reduction in unsatisfactory Pap tests. The relative risk of an unsatisfactory Pap test in women aged ≥50 years increased after the transition to LBPs (SurePath: relative risk, 2.1; 95% CI, 1.9-2.2; ThinPrep: relative risk, 1.7; 95% CI, 1.5-2.0).</p></div></div>
<div class="section" id="cncy21309-sec-0004" xmlns="http://www.w3.org/1999/xhtml"><h4>CONCLUSIONS</h4><div class="para"><p>The observed changes in the proportion of unsatisfactory Pap tests varied across the participating sites and depended on the type of LBP technology, the age of women, and the rates before the implementation of this technology. Cancer (Cancer Cytopathol) 2013. © 2013 American Cancer Society.</p></div></div>
]]></content:encoded><description>

BACKGROUND
Papanicolaou (Pap) testing has transitioned from conventional preparations (CPs) to liquid-based preparations (LBPs) because of the perceived superiority of LBPs. Many studies conclude that LBPs reduce unsatisfactory Pap tests; however, some believe that the evidence substantiating this claim is weak. The authors studied the effect of the transition from CPs to LBPs on the proportion of unsatisfactory Pap tests in 4 health care systems in the United States participating in the National Institutes of Health-funded Screening Effectiveness and Research in Community-Based Healthcare (SEARCH) project.


METHODS
The study cohort consisted of 548,174 women ages 21 to 65 years who had 1443,725 total Pap tests between 2000 and 2010. Segmented regression analysis was used to estimate the effect of adopting LBPs on the proportion of unsatisfactory Pap tests after adjusting for age.


RESULTS
Three sites that implemented SurePath LBP experienced significant reductions in unsatisfactory Pap tests (estimated effect: site 1, −2.46%; 95% confidence interval [CI], −1.47%, −3.45%; site 2, −1.78%; 95% CI, −1.54%, −2.02%; site 3, −8.25%; 95% CI, −7.33%, −9.17%). The fourth site that implemented ThinPrep LBP did not experience a reduction in unsatisfactory Pap tests. The relative risk of an unsatisfactory Pap test in women aged ≥50 years increased after the transition to LBPs (SurePath: relative risk, 2.1; 95% CI, 1.9-2.2; ThinPrep: relative risk, 1.7; 95% CI, 1.5-2.0).


CONCLUSIONS
The observed changes in the proportion of unsatisfactory Pap tests varied across the participating sites and depended on the type of LBP technology, the age of women, and the rates before the implementation of this technology. Cancer (Cancer Cytopathol) 2013. © 2013 American Cancer Society.

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21303" xmlns="http://purl.org/rss/1.0/"><title>Improving the accuracy of pancreatobiliary tract cytology with fluorescence in situ hybridization: A molecular test with proven clinical success</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21303</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Improving the accuracy of pancreatobiliary tract cytology with fluorescence in situ hybridization: A molecular test with proven clinical success</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Benjamin R. Kipp, Emily G. Barr Fritcher, Jennifer E. Pettengill, Kevin C. Halling, Amy C. Clayton</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-04-30T11:21:59.031282-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/cncy.21303</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/cncy.21303</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21303</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Review Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<div class="para" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib" xmlns="http://www.w3.org/1999/xhtml"><p>The detection of aneuploidy by fluorescence in situ hybridization (FISH) has revolutionized how laboratories diagnose cholangiocarcinoma and pancreatic adenocarcinoma using cytology specimens. Numerous clinical studies have demonstrated that FISH increases the diagnostic sensitivity of routine cytology for detecting pancreatobiliary tract malignancy with minimal decreases in clinical specificity. FISH also provides useful information in difficult clinical scenarios, including the assessment of patients with biliary strictures who have equivocal cytology results and the assessment of patients with primary sclerosing cholangitis who have clinical features suggestive of malignancy. The improved ability to detect pancreatobiliary tract cancers offers the possibility of earlier detection when patients are amenable to surgical intervention and can decrease health care costs by reducing the amount of clinical evaluation required to arrive at a cancer diagnosis. Cytopathology personnel should maintain familiarity with molecular cytology testing methodologies, because morphologic and aneuploidy assessment of tumors will continue to be an integral part of large-scale genome analyses of individual tumors. <b><em>Cancer (Cancer Cytopathol)</em> 2013;</b>. © <em>2013 American Cancer Society</em>.</p></div>
]]></content:encoded><description>
The detection of aneuploidy by fluorescence in situ hybridization (FISH) has revolutionized how laboratories diagnose cholangiocarcinoma and pancreatic adenocarcinoma using cytology specimens. Numerous clinical studies have demonstrated that FISH increases the diagnostic sensitivity of routine cytology for detecting pancreatobiliary tract malignancy with minimal decreases in clinical specificity. FISH also provides useful information in difficult clinical scenarios, including the assessment of patients with biliary strictures who have equivocal cytology results and the assessment of patients with primary sclerosing cholangitis who have clinical features suggestive of malignancy. The improved ability to detect pancreatobiliary tract cancers offers the possibility of earlier detection when patients are amenable to surgical intervention and can decrease health care costs by reducing the amount of clinical evaluation required to arrive at a cancer diagnosis. Cytopathology personnel should maintain familiarity with molecular cytology testing methodologies, because morphologic and aneuploidy assessment of tumors will continue to be an integral part of large-scale genome analyses of individual tumors. Cancer (Cancer Cytopathol) 2013;. © 2013 American Cancer Society.
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21301" xmlns="http://purl.org/rss/1.0/"><title>Application of the ThinPrep Imaging System in urine cytology</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21301</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Application of the ThinPrep Imaging System in urine cytology</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Bettien M. van Hemel, Jolanda G. Haarsma, Teus Ruitenbeek, Henk J. Groen, Albert J. H. Suurmeijer</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-04-23T11:08:15.099687-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/cncy.21301</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/cncy.21301</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21301</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<div class="section" id="cncy21301-sec-0001" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib" xmlns="http://www.w3.org/1999/xhtml"><h4>BACKGROUND</h4><div class="para"><p>In this prospective study, for the first time, the authors compared the accuracy of reading urine specimens using the ThinPrep Imager System (TIS) with the accuracy of conventional screening for the detection of abnormal urine cells.</p></div></div>
<div class="section" id="cncy21301-sec-0002" xmlns="http://www.w3.org/1999/xhtml"><h4>METHODS</h4><div class="para"><p>ThinPrep slides were made from 1455 urine specimens and were read with conventional screening and with TIS. Findings were categorized as “unsatisfactory or failure to read the slide,” “benign,” or “abnormal.” The Cohen κ coefficient was calculated to determine inter-rater agreement between both methods. Urine samples that were followed by biopsies were used to compare the sensitivity, specificity, positive predictive value, and negative predictive value of both methods. From 22 urine specimens, the screening times were measured and compared.</p></div></div>
<div class="section" id="cncy21301-sec-0003" xmlns="http://www.w3.org/1999/xhtml"><h4>RESULTS</h4><div class="para"><p>There was substantial agreement between both methods (κ score, 0.77). Of 175 urine specimens that were followed by bladder biopsies, for conventional screening, the sensitivity was 51.3%, specificity was 68.4%, the positive predictive value was 77.2%, and the negative predictive value was 40.2%; for TIS screening, the respective values were 54.6%, 68.4%, 78.3%, and 41.9%. The average time was 5.2 minutes for conventional screening and 3.9 minutes for TIS.</p></div></div>
<div class="section" id="cncy21301-sec-0004" xmlns="http://www.w3.org/1999/xhtml"><h4>CONCLUSIONS</h4><div class="para"><p>With a κ score of 0.77, the current study demonstrated a good correlation between reading urine specimens with conventional screening and with TIS. Using TIS resulted in slightly increased sensitivity, positive predictive value, and negative predictive value compared with conventional screening and had the same specificity. These results indicate that reading urine specimens using TIS is equally reliable as conventional cytology. <b><em>Cancer (Cancer Cytopathol)</em> 2013;</b>. © <em>2013 American Cancer Society</em>.</p></div></div>
]]></content:encoded><description>

BACKGROUND
In this prospective study, for the first time, the authors compared the accuracy of reading urine specimens using the ThinPrep Imager System (TIS) with the accuracy of conventional screening for the detection of abnormal urine cells.


METHODS
ThinPrep slides were made from 1455 urine specimens and were read with conventional screening and with TIS. Findings were categorized as “unsatisfactory or failure to read the slide,” “benign,” or “abnormal.” The Cohen κ coefficient was calculated to determine inter-rater agreement between both methods. Urine samples that were followed by biopsies were used to compare the sensitivity, specificity, positive predictive value, and negative predictive value of both methods. From 22 urine specimens, the screening times were measured and compared.


RESULTS
There was substantial agreement between both methods (κ score, 0.77). Of 175 urine specimens that were followed by bladder biopsies, for conventional screening, the sensitivity was 51.3%, specificity was 68.4%, the positive predictive value was 77.2%, and the negative predictive value was 40.2%; for TIS screening, the respective values were 54.6%, 68.4%, 78.3%, and 41.9%. The average time was 5.2 minutes for conventional screening and 3.9 minutes for TIS.


CONCLUSIONS
With a κ score of 0.77, the current study demonstrated a good correlation between reading urine specimens with conventional screening and with TIS. Using TIS resulted in slightly increased sensitivity, positive predictive value, and negative predictive value compared with conventional screening and had the same specificity. These results indicate that reading urine specimens using TIS is equally reliable as conventional cytology. Cancer (Cancer Cytopathol) 2013;. © 2013 American Cancer Society.

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21300" xmlns="http://purl.org/rss/1.0/"><title>Imaging systems and urine specimens</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21300</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Imaging systems and urine specimens</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Tatjana Antic</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-04-23T11:08:06.827536-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/cncy.21300</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/cncy.21300</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21300</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Editorial</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<div class="para" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib" xmlns="http://www.w3.org/1999/xhtml"><p>The application of standard cytologic examination of the urine specimen can now be augmented by using ThinPrep technology and other automatic screening devices. The technical and preparation adjustments required for these new technologies notwithstanding, the potential for shorter screening times and the possibility of greater diagnostic accuracy may provide great diagnostic promise for this very common specimen. <b><em>Cancer (Cancer Cytopathol)</em> 2013;</b>. © <em>2013 American Cancer Society</em>.</p></div>
]]></content:encoded><description>
The application of standard cytologic examination of the urine specimen can now be augmented by using ThinPrep technology and other automatic screening devices. The technical and preparation adjustments required for these new technologies notwithstanding, the potential for shorter screening times and the possibility of greater diagnostic accuracy may provide great diagnostic promise for this very common specimen. Cancer (Cancer Cytopathol) 2013;. © 2013 American Cancer Society.
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21297" xmlns="http://purl.org/rss/1.0/"><title>Pooled analysis of the performance of liquid-based cytology in population-based cervical cancer screening studies in China</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21297</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Pooled analysis of the performance of liquid-based cytology in population-based cervical cancer screening studies in China</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Qin-Jing Pan, Shang-ying Hu, Xun Zhang, Pu-wa Ci, Wen-hua Zhang, Hui-qin Guo, Jian Cao, Fang-hui Zhao, Alice Lytwyn,, You-lin Qiao</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-04-23T11:08:01.336139-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/cncy.21297</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/cncy.21297</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21297</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<div class="section" id="cncy21297-sec-0001" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib" xmlns="http://www.w3.org/1999/xhtml"><h4>BACKGROUND</h4><div class="para"><p>Liquid-based cytology (LBC) has been widely used for cervical cancer screening. Despite numerous studies and systematic reviews, to the authors' knowledge few large studies to date have focused on biopsy-confirmed cervical lesions and controversy remains concerning its diagnostic accuracy. The objective of the current study was to assess LBC for detecting biopsy-confirmed cervical intraepithelial neoplasia (CIN) and cancer.</p></div></div>
<div class="section" id="cncy21297-sec-0002" xmlns="http://www.w3.org/1999/xhtml"><h4>METHODS</h4><div class="para"><p>A pooled analysis of LBC using data from 13 population-based, cross-sectional, cervical cancer screening studies performed in China from 1999 to 2008 was performed. Participants (n = 26,782) received LBC and human papillomavirus testing. Women found to be positive on screening were referred for colposcopy and biopsy. The accuracy of LBC for detecting biopsy-confirmed CIN of type 2 or worse (CIN2+) as well as CIN type 3 or worse (CIN3+) lesions was analyzed.</p></div></div>
<div class="section" id="cncy21297-sec-0003" xmlns="http://www.w3.org/1999/xhtml"><h4>RESULTS</h4><div class="para"><p>Of 25,830 women included in the analysis, CIN2+ was found in 107 of 2612 with atypical squamous cells (4.1%), 142 of 923 with low-grade squamous intraepithelial neoplasia (15.4%), 512 of 784 with high-grade squamous intraepithelial neoplasia (65.3%), 29 of 30 with squamous cell carcinoma (96.7%), 4 of 27 with atypical glandular cells (14.8%), and 85 of 21,454 with normal cytology results (0.4%). No invasive cancers were found to have atypical squamous cells, atypical glandular cells, or cytologically normal slides. The overall sensitivity, specificity, positive predictive value, negative predictive value, and accuracy of LBC for detecting CIN2+ were 81.0%, 95.4%, 38.3%, 99.3 %, and 94.9%, respectively. Although Hybrid Capture 2 was more sensitive than LBC, the specificity, positive predictive value, and overall accuracy of LBC were higher than those of Hybrid Capture2 at 85.2%, 18.6%, and 85.5%, respectively.</p></div></div>
<div class="section" id="cncy21297-sec-0004" xmlns="http://www.w3.org/1999/xhtml"><h4>CONCLUSIONS</h4><div class="para"><p>The results of the current study indicate that the performance of LBC can effectively predict the risk of existing CIN2+ and may be a good screening tool for cervical cancer prevention in a developing country. <b><em>Cancer (Cancer Cytopathol)</em> 2013;</b>. © <em>2013 American Cancer Society</em>.</p></div></div>
]]></content:encoded><description>

BACKGROUND
Liquid-based cytology (LBC) has been widely used for cervical cancer screening. Despite numerous studies and systematic reviews, to the authors' knowledge few large studies to date have focused on biopsy-confirmed cervical lesions and controversy remains concerning its diagnostic accuracy. The objective of the current study was to assess LBC for detecting biopsy-confirmed cervical intraepithelial neoplasia (CIN) and cancer.


METHODS
A pooled analysis of LBC using data from 13 population-based, cross-sectional, cervical cancer screening studies performed in China from 1999 to 2008 was performed. Participants (n = 26,782) received LBC and human papillomavirus testing. Women found to be positive on screening were referred for colposcopy and biopsy. The accuracy of LBC for detecting biopsy-confirmed CIN of type 2 or worse (CIN2+) as well as CIN type 3 or worse (CIN3+) lesions was analyzed.


RESULTS
Of 25,830 women included in the analysis, CIN2+ was found in 107 of 2612 with atypical squamous cells (4.1%), 142 of 923 with low-grade squamous intraepithelial neoplasia (15.4%), 512 of 784 with high-grade squamous intraepithelial neoplasia (65.3%), 29 of 30 with squamous cell carcinoma (96.7%), 4 of 27 with atypical glandular cells (14.8%), and 85 of 21,454 with normal cytology results (0.4%). No invasive cancers were found to have atypical squamous cells, atypical glandular cells, or cytologically normal slides. The overall sensitivity, specificity, positive predictive value, negative predictive value, and accuracy of LBC for detecting CIN2+ were 81.0%, 95.4%, 38.3%, 99.3 %, and 94.9%, respectively. Although Hybrid Capture 2 was more sensitive than LBC, the specificity, positive predictive value, and overall accuracy of LBC were higher than those of Hybrid Capture2 at 85.2%, 18.6%, and 85.5%, respectively.


CONCLUSIONS
The results of the current study indicate that the performance of LBC can effectively predict the risk of existing CIN2+ and may be a good screening tool for cervical cancer prevention in a developing country. Cancer (Cancer Cytopathol) 2013;. © 2013 American Cancer Society.

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21292" xmlns="http://purl.org/rss/1.0/"><title>Use of touch imprint cytology as a simple method to enrich tumor cells for molecular analysis</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21292</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Use of touch imprint cytology as a simple method to enrich tumor cells for molecular analysis</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Snjezana Dogan, Jillian C. Becker, Natasha Rekhtman, Laura H. Tang, Khedoudja Nafa, Marc Ladanyi, David S. Klimstra</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-04-10T10:52:26.548288-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/cncy.21292</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/cncy.21292</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21292</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<div class="section" id="cncy21292-sec-0001" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib" xmlns="http://www.w3.org/1999/xhtml"><h4>BACKGROUND</h4><div class="para"><p>A relative excess of nonneoplastic cells in frozen carcinoma samples is often a cause of false-negative results in molecular assays. Given the greater cohesiveness of epithelial tumor cells compared with nonneoplastic epithelium and mesenchymal stroma, the authors hypothesized that tumor procurement by touch imprinting would provide a simple, cost-effective method of obtaining enriched neoplastic cells compared with frozen whole-tumor samples.</p></div></div>
<div class="section" id="cncy21292-sec-0002" xmlns="http://www.w3.org/1999/xhtml"><h4>METHODS</h4><div class="para"><p>Eleven adenocarcinomas with known <em>KRAS</em> gene mutations were tested. Two sets of 8 touch imprint (TP) slides and 1 frozen whole-tumor sample (FS), both with a corresponding hematoxylin and eosin-stained slide, were obtained from each tumor. DNA from unstained TP and FS samples was tested for <em>KRAS</em> exon 2 mutations by Sanger sequencing. The percentage of carcinoma cells was determined by light microscopy of hematoxylin and eosin-stained slides. The fold increase in the mutant-enriched DNA in TP versus FS samples was determined by calculating the height ratio between the mutant and wild-type peaks on the sequencing electropherogram.</p></div></div>
<div class="section" id="cncy21292-sec-0003" xmlns="http://www.w3.org/1999/xhtml"><h4>RESULTS</h4><div class="para"><p>Using light microscopy, TP demonstrated a 1.1-fold to 3.5-fold (mean, 1.8-fold) enrichment in neoplastic cells compared with the FS. The mutant–to–wild-type peak height ratio was 1.4-fold to 7.1-fold (mean, 3.1-fold) higher in TP compared with the corresponding FS samples. The average amount of extracted DNA ranged from 145 ng to 7.9 μg per TP slide.</p></div></div>
<div class="section" id="cncy21292-sec-0004" xmlns="http://www.w3.org/1999/xhtml"><h4>CONCLUSIONS</h4><div class="para"><p>The procurement of carcinoma samples by TP is rapid, simple, and inexpensive; consistently provides a tumor-enriched sample; is an excellent source of high-quality tumor DNA; and could compensate for the relatively low sensitivity of direct sequencing. <b><em>Cancer (Cancer Cytopathol)</em> 2013.</b> © <em>2013 American Cancer Society</em>.</p></div></div>
]]></content:encoded><description>

BACKGROUND
A relative excess of nonneoplastic cells in frozen carcinoma samples is often a cause of false-negative results in molecular assays. Given the greater cohesiveness of epithelial tumor cells compared with nonneoplastic epithelium and mesenchymal stroma, the authors hypothesized that tumor procurement by touch imprinting would provide a simple, cost-effective method of obtaining enriched neoplastic cells compared with frozen whole-tumor samples.


METHODS
Eleven adenocarcinomas with known KRAS gene mutations were tested. Two sets of 8 touch imprint (TP) slides and 1 frozen whole-tumor sample (FS), both with a corresponding hematoxylin and eosin-stained slide, were obtained from each tumor. DNA from unstained TP and FS samples was tested for KRAS exon 2 mutations by Sanger sequencing. The percentage of carcinoma cells was determined by light microscopy of hematoxylin and eosin-stained slides. The fold increase in the mutant-enriched DNA in TP versus FS samples was determined by calculating the height ratio between the mutant and wild-type peaks on the sequencing electropherogram.


RESULTS
Using light microscopy, TP demonstrated a 1.1-fold to 3.5-fold (mean, 1.8-fold) enrichment in neoplastic cells compared with the FS. The mutant–to–wild-type peak height ratio was 1.4-fold to 7.1-fold (mean, 3.1-fold) higher in TP compared with the corresponding FS samples. The average amount of extracted DNA ranged from 145 ng to 7.9 μg per TP slide.


CONCLUSIONS
The procurement of carcinoma samples by TP is rapid, simple, and inexpensive; consistently provides a tumor-enriched sample; is an excellent source of high-quality tumor DNA; and could compensate for the relatively low sensitivity of direct sequencing. Cancer (Cancer Cytopathol) 2013. © 2013 American Cancer Society.

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21291" xmlns="http://purl.org/rss/1.0/"><title>Fine-needle aspiration diagnosis of lymphomas with signet ring cell features</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21291</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Fine-needle aspiration diagnosis of lymphomas with signet ring cell features</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Jeff Wang, Ruth L. Katz, John Stewart, Gene Landon, Ming Guo, Yun Gong</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-03-27T09:26:34.660574-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/cncy.21291</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/cncy.21291</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21291</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<div class="section" id="cncy21291-sec-0001" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib" xmlns="http://www.w3.org/1999/xhtml"><h4>BACKGROUND</h4><div class="para"><p>Lymphoma with signet ring cell features (LSF) is a rare morphologic variant of non-Hodgkin lymphoma. Although it has been well documented in the surgical pathology literature, to the best of the authors's knowledge, the features of LSF in fine-needle aspiration (FNA) samples have rarely been reported. An accurate cytologic diagnosis of LSF is of important therapeutic significance.</p></div></div>
<div class="section" id="cncy21291-sec-0002" xmlns="http://www.w3.org/1999/xhtml"><h4>METHODS</h4><div class="para"><p>The authors retrospectively reviewed 7 FNA cases of LSF for cytologic features, ancillary studies, corresponding histologic findings, and the patients' clinical and radiologic information to illustrate the diagnostic clues and potential pitfalls.</p></div></div>
<div class="section" id="cncy21291-sec-0003" xmlns="http://www.w3.org/1999/xhtml"><h4>RESULTS</h4><div class="para"><p>The final diagnoses, based on a multidisciplinary approach, were follicular lymphoma (5 patients), large B-cell lymphoma of follicular center cell origin (1 patient), and low-grade B-cell lymphoma with plasmacytoid features (1 patient). FNAs were obtained from both lymph node and extranodal sites. Common cytologic features included various percentages of signet ring cells in a background of nonvacuolated lymphomatous cells, lymphoglandular bodies, and cytoplasmic rings. The majority of signet ring cells contained a single, large, clear intracytoplasmic vacuole that pushed the nucleus laterally whereas fewer cells contained ≥ 2 vacuoles that indented the nucleus into a scalloped or stellate configuration. These cells resemble, to some degree, other lesions with signet ring cell features. One of the diagnostic clues of LSF was the similarity in nuclear details between signet ring cells and surrounding nonvacuolated lymphoid cells.</p></div></div>
<div class="section" id="cncy21291-sec-0004" xmlns="http://www.w3.org/1999/xhtml"><h4>CONCLUSIONS</h4><div class="para"><p>Familiarity with cytologic features, correlation with clinical/radiologic information, and ancillary studies are important for an accurate diagnosis of LSF and for distinguishing it from other lesions with signet ring cell features in FNA samples. <b><em>Cancer (Cancer Cytopathol)</em> 2013.</b> © <em>2013 American Cancer Society</em>.</p></div></div>
]]></content:encoded><description>

BACKGROUND
Lymphoma with signet ring cell features (LSF) is a rare morphologic variant of non-Hodgkin lymphoma. Although it has been well documented in the surgical pathology literature, to the best of the authors's knowledge, the features of LSF in fine-needle aspiration (FNA) samples have rarely been reported. An accurate cytologic diagnosis of LSF is of important therapeutic significance.


METHODS
The authors retrospectively reviewed 7 FNA cases of LSF for cytologic features, ancillary studies, corresponding histologic findings, and the patients' clinical and radiologic information to illustrate the diagnostic clues and potential pitfalls.


RESULTS
The final diagnoses, based on a multidisciplinary approach, were follicular lymphoma (5 patients), large B-cell lymphoma of follicular center cell origin (1 patient), and low-grade B-cell lymphoma with plasmacytoid features (1 patient). FNAs were obtained from both lymph node and extranodal sites. Common cytologic features included various percentages of signet ring cells in a background of nonvacuolated lymphomatous cells, lymphoglandular bodies, and cytoplasmic rings. The majority of signet ring cells contained a single, large, clear intracytoplasmic vacuole that pushed the nucleus laterally whereas fewer cells contained ≥ 2 vacuoles that indented the nucleus into a scalloped or stellate configuration. These cells resemble, to some degree, other lesions with signet ring cell features. One of the diagnostic clues of LSF was the similarity in nuclear details between signet ring cells and surrounding nonvacuolated lymphoid cells.


CONCLUSIONS
Familiarity with cytologic features, correlation with clinical/radiologic information, and ancillary studies are important for an accurate diagnosis of LSF and for distinguishing it from other lesions with signet ring cell features in FNA samples. Cancer (Cancer Cytopathol) 2013. © 2013 American Cancer Society.

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21290" xmlns="http://purl.org/rss/1.0/"><title>Standardizing preanalytical variables for molecular cytopathology</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21290</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Standardizing preanalytical variables for molecular cytopathology</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Gilda da Cunha Santos</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-03-27T09:26:22.110341-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/cncy.21290</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/cncy.21290</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21290</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Editorial</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<div class="para" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib" xmlns="http://www.w3.org/1999/xhtml"><p>Standardized protocols for the fixation and handling of cytological specimens are required for reliable, consistent, and robust molecular test results for the assessment of biomarkers to direct patient selection for targeted therapies. This editorial discusses the strengths and limitations of the article by Dejmek et al with regard to this topic.</p></div>
]]></content:encoded><description>
Standardized protocols for the fixation and handling of cytological specimens are required for reliable, consistent, and robust molecular test results for the assessment of biomarkers to direct patient selection for targeted therapies. This editorial discusses the strengths and limitations of the article by Dejmek et al with regard to this topic.
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21286" xmlns="http://purl.org/rss/1.0/"><title>The use of stained cytologic direct smears for ALK gene rearrangement analysis of lung adenocarcinoma</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21286</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">The use of stained cytologic direct smears for ALK gene rearrangement analysis of lung adenocarcinoma</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Bryan L. Betz, Catherine A. Dixon, Helmut C. Weigelin, Stewart M. Knoepp, Michael H. Roh</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-03-27T09:26:16.632796-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/cncy.21286</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/cncy.21286</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21286</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<div class="section" id="cncy21286-sec-0001" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib" xmlns="http://www.w3.org/1999/xhtml"><h4>BACKGROUND</h4><div class="para"><p>Rearrangements involving the anaplastic lymphoma kinase (<em>ALK</em>) gene are present in approximately 5% of lung adenocarcinomas. Crizotinib is approved for the treatment of lung adenocarcinomas harboring <em>ALK</em> rearrangements. Patients with advanced stage lung cancer are not candidates for surgical resection of their primary tumors. For these patients, cytologic specimens often represent the only diagnostic tissue available. Cell blocks (CBs) are routinely used for molecular studies; however, insufficient CB cellularity can impede the performance of these assays.</p></div></div>
<div class="section" id="cncy21286-sec-0002" xmlns="http://www.w3.org/1999/xhtml"><h4>METHODS</h4><div class="para"><p>Thirty-two cytology cases of lung adenocarcinomas were analyzed by fluorescence in situ hybridization (FISH) for <em>ALK</em> rearrangements. Diff-Quik–stained smears were examined to identify tumor cell-enriched areas that were marked using a diamond-tipped scribe. Paired <em>ALK</em> rearrangement FISH was performed using smears and CBs in each case.</p></div></div>
<div class="section" id="cncy21286-sec-0003" xmlns="http://www.w3.org/1999/xhtml"><h4>RESULTS</h4><div class="para"><p>An <em>ALK</em> rearrangement was detected on direct smears and CB sections in 5 (16%) and 4 (13%), respectively, of the 32 cases studied. Concordant FISH results for smears and CBs were observed in 31 (97%) of 32 cases. In the 1 discordant case, an <em>ALK</em> rearrangement was detected on the direct smear but not in the CB. Reverse transcriptase-polymerase chain reaction analysis of this CB revealed the presence of an <em>EML4-ALK</em> rearrangement, thereby confirming a false-negative FISH result in the CB.</p></div></div>
<div class="section" id="cncy21286-sec-0004" xmlns="http://www.w3.org/1999/xhtml"><h4>CONCLUSIONS</h4><div class="para"><p>Stained cytologic direct smears can be effectively used for <em>ALK</em> rearrangement analysis by FISH. This approach represents a useful safeguard when insufficient CB cellularity is encountered and could prevent delays in treatment in this era of precision medicine. <b><em>Cancer (Cancer Cytopathol)</em> 2013.</b> © <em>2013 American Cancer Society</em>.</p></div></div>
]]></content:encoded><description>

BACKGROUND
Rearrangements involving the anaplastic lymphoma kinase (ALK) gene are present in approximately 5% of lung adenocarcinomas. Crizotinib is approved for the treatment of lung adenocarcinomas harboring ALK rearrangements. Patients with advanced stage lung cancer are not candidates for surgical resection of their primary tumors. For these patients, cytologic specimens often represent the only diagnostic tissue available. Cell blocks (CBs) are routinely used for molecular studies; however, insufficient CB cellularity can impede the performance of these assays.


METHODS
Thirty-two cytology cases of lung adenocarcinomas were analyzed by fluorescence in situ hybridization (FISH) for ALK rearrangements. Diff-Quik–stained smears were examined to identify tumor cell-enriched areas that were marked using a diamond-tipped scribe. Paired ALK rearrangement FISH was performed using smears and CBs in each case.


RESULTS
An ALK rearrangement was detected on direct smears and CB sections in 5 (16%) and 4 (13%), respectively, of the 32 cases studied. Concordant FISH results for smears and CBs were observed in 31 (97%) of 32 cases. In the 1 discordant case, an ALK rearrangement was detected on the direct smear but not in the CB. Reverse transcriptase-polymerase chain reaction analysis of this CB revealed the presence of an EML4-ALK rearrangement, thereby confirming a false-negative FISH result in the CB.


CONCLUSIONS
Stained cytologic direct smears can be effectively used for ALK rearrangement analysis by FISH. This approach represents a useful safeguard when insufficient CB cellularity is encountered and could prevent delays in treatment in this era of precision medicine. Cancer (Cancer Cytopathol) 2013. © 2013 American Cancer Society.

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21278" xmlns="http://purl.org/rss/1.0/"><title>Evaluation of atypical urine cytology progression to malignancy</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21278</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Evaluation of atypical urine cytology progression to malignancy</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Julianne Muus Ubago, Vikas Mehta, Eva M. Wojcik, Güliz A. Barkan</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-03-27T09:25:52.112046-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/cncy.21278</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/cncy.21278</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21278</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<div class="section" id="cncy21278-sec-0001" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib" xmlns="http://www.w3.org/1999/xhtml"><h4>BACKGROUND</h4><div class="para"><p>In urine cytology, the diagnosis of atypia is subjective and clinical management based on these results can be difficult to determine. In this study, the authors determined the percentage of atypical urine diagnoses that progressed to positive cytology or surgical pathology results over an 11-year period.</p></div></div>
<div class="section" id="cncy21278-sec-0002" xmlns="http://www.w3.org/1999/xhtml"><h4>METHODS</h4><div class="para"><p>In a retrospective review of the authors’ institution, 1320 atypical urine cytology diagnoses were identified in specimens from 851 patients obtained from January 2000 through December 2010. All subsequent pathology reports were reviewed to determine which patients developed positive cytology/surgical pathology diagnoses. In total, 4106 cytology and surgical pathology specimen reports were reviewed.</p></div></div>
<div class="section" id="cncy21278-sec-0003" xmlns="http://www.w3.org/1999/xhtml"><h4>RESULTS</h4><div class="para"><p>At the authors’ institution, 1320 of 16,299 of urine cytology specimens (8.1%) were diagnosed as atypical during the 11-year period. Overall, 271 of 1320 initial atypical urine specimens (21%) progressed to positive cytology or surgical pathology results with a mean time to progression of 155 days. Of the cases that progressed to malignancy, 118 were high-grade urothelial carcinoma and 92 were low-grade urothelial carcinoma.</p></div></div>
<div class="section" id="cncy21278-sec-0004" xmlns="http://www.w3.org/1999/xhtml"><h4>CONCLUSIONS</h4><div class="para"><p>The rate of atypia in urine specimens at this institution was 8.1%. Of the specimen types, atypia was the most common in urinary diversion specimens (16%) and the least common in upper tract cytology (3.8%). When diagnosed as atypical, upper tract specimens had the highest percentage of progression to high-grade carcinoma. Therefore, the authors concluded that the diagnosis of atypia in this specimen group has higher clinical significance and should be managed more aggressively. <b><em>Cancer (Cancer Cytopathol)</em> 2013.</b> © <em>2013 American Cancer Society</em>.</p></div></div>
]]></content:encoded><description>

BACKGROUND
In urine cytology, the diagnosis of atypia is subjective and clinical management based on these results can be difficult to determine. In this study, the authors determined the percentage of atypical urine diagnoses that progressed to positive cytology or surgical pathology results over an 11-year period.


METHODS
In a retrospective review of the authors’ institution, 1320 atypical urine cytology diagnoses were identified in specimens from 851 patients obtained from January 2000 through December 2010. All subsequent pathology reports were reviewed to determine which patients developed positive cytology/surgical pathology diagnoses. In total, 4106 cytology and surgical pathology specimen reports were reviewed.


RESULTS
At the authors’ institution, 1320 of 16,299 of urine cytology specimens (8.1%) were diagnosed as atypical during the 11-year period. Overall, 271 of 1320 initial atypical urine specimens (21%) progressed to positive cytology or surgical pathology results with a mean time to progression of 155 days. Of the cases that progressed to malignancy, 118 were high-grade urothelial carcinoma and 92 were low-grade urothelial carcinoma.


CONCLUSIONS
The rate of atypia in urine specimens at this institution was 8.1%. Of the specimen types, atypia was the most common in urinary diversion specimens (16%) and the least common in upper tract cytology (3.8%). When diagnosed as atypical, upper tract specimens had the highest percentage of progression to high-grade carcinoma. Therefore, the authors concluded that the diagnosis of atypia in this specimen group has higher clinical significance and should be managed more aggressively. Cancer (Cancer Cytopathol) 2013. © 2013 American Cancer Society.

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21288" xmlns="http://purl.org/rss/1.0/"><title>Identification of EGFR mutation, KRAS mutation, and ALK gene rearrangement in cytological specimens of primary and metastatic lung adenocarcinoma</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21288</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Identification of EGFR mutation, KRAS mutation, and ALK gene rearrangement in cytological specimens of primary and metastatic lung adenocarcinoma</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Guoping Cai, Rebecca Wong, David Chhieng, Gillian H. Levy, Scott N. Gettinger, Roy S. Herbst, Jonathan T. Puchalski, Robert J. Homer, Pei Hui</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-03-12T15:22:55.869414-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/cncy.21288</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/cncy.21288</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21288</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<div class="section" id="cncy21288-sec-0001" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib" xmlns="http://www.w3.org/1999/xhtml"><h4>BACKGROUND</h4><div class="para"><p>The identification of molecular alterations has an important therapeutic implication in patients with lung adenocarcinomas. In the current study, the authors evaluated their experience with the identification of epidermal growth factor receptor (<em>EGFR</em>), Kirsten rat sarcoma viral oncogene homolog (<em>KRAS</em>) mutation, and anaplastic lymphoma kinase (<em>ALK</em>) gene rearrangement using cytological specimens of primary and metastatic lung adenocarcinoma.</p></div></div>
<div class="section" id="cncy21288-sec-0002" xmlns="http://www.w3.org/1999/xhtml"><h4>METHODS</h4><div class="para"><p>A total of 54 cases of lung adenocarcinomas (11 primary and 43 metastatic tumors) in which molecular tests were performed were retrieved. Molecular tests were performed on the cell block material of 19 effusions and 35 fine-needle aspirates. <em>EGFR</em> mutation was evaluated by polymerase chain reaction sequencing analysis of exons 18, 19, 20, and 21. <em>KRAS</em> mutation was tested using polymerase chain reaction–single-strand conformational polymorphism analysis of codons 12 and 13. <em>ALK</em> gene rearrangement was evaluated by fluorescence in situ hybridization using an <em>ALK</em> break apart probe.</p></div></div>
<div class="section" id="cncy21288-sec-0003" xmlns="http://www.w3.org/1999/xhtml"><h4>RESULTS</h4><div class="para"><p>Molecular tests were successful in 49 of 54 cases (91%). Evaluation of <em>EGFR</em> mutation, <em>KRAS</em> mutation, and <em>ALK</em> gene rearrangement were performed in 49 cases, 14 cases, and 22 cases, respectively. <em>EGFR</em> mutations were found in 14 of 49 cases (29%), including 5 primary and 9 metastatic tumors. Three metastatic/recurrent adenocarcinomas demonstrated an additional <em>EGFR</em> T790M mutation that was not identified in the original specimens. <em>KRAS</em> mutation was detected in 3 of 14 cases (21%) including 1 primary and 2 metastatic tumors. <em>ALK</em> gene rearrangement was evident in 3 of 22 cases (14%), all of which were metastatic tumors.</p></div></div>
<div class="section" id="cncy21288-sec-0004" xmlns="http://www.w3.org/1999/xhtml"><h4>CONCLUSIONS</h4><div class="para"><p>The results of the current study have demonstrated the feasibility of using cytological specimens for <em>EGFR</em> mutation, <em>KRAS</em> mutation, and <em>ALK</em> gene rearrangement analysis. Repeating molecular testing in metastatic/recurrent lung adenocarcinomas may uncover newly acquired molecular alterations. <b><em>Cancer (Cancer Cytopathol)</em> 2013;</b> © <em>2013 American Cancer Society</em>.</p></div></div>
]]></content:encoded><description>

BACKGROUND
The identification of molecular alterations has an important therapeutic implication in patients with lung adenocarcinomas. In the current study, the authors evaluated their experience with the identification of epidermal growth factor receptor (EGFR), Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation, and anaplastic lymphoma kinase (ALK) gene rearrangement using cytological specimens of primary and metastatic lung adenocarcinoma.


METHODS
A total of 54 cases of lung adenocarcinomas (11 primary and 43 metastatic tumors) in which molecular tests were performed were retrieved. Molecular tests were performed on the cell block material of 19 effusions and 35 fine-needle aspirates. EGFR mutation was evaluated by polymerase chain reaction sequencing analysis of exons 18, 19, 20, and 21. KRAS mutation was tested using polymerase chain reaction–single-strand conformational polymorphism analysis of codons 12 and 13. ALK gene rearrangement was evaluated by fluorescence in situ hybridization using an ALK break apart probe.


RESULTS
Molecular tests were successful in 49 of 54 cases (91%). Evaluation of EGFR mutation, KRAS mutation, and ALK gene rearrangement were performed in 49 cases, 14 cases, and 22 cases, respectively. EGFR mutations were found in 14 of 49 cases (29%), including 5 primary and 9 metastatic tumors. Three metastatic/recurrent adenocarcinomas demonstrated an additional EGFR T790M mutation that was not identified in the original specimens. KRAS mutation was detected in 3 of 14 cases (21%) including 1 primary and 2 metastatic tumors. ALK gene rearrangement was evident in 3 of 22 cases (14%), all of which were metastatic tumors.


CONCLUSIONS
The results of the current study have demonstrated the feasibility of using cytological specimens for EGFR mutation, KRAS mutation, and ALK gene rearrangement analysis. Repeating molecular testing in metastatic/recurrent lung adenocarcinomas may uncover newly acquired molecular alterations. Cancer (Cancer Cytopathol) 2013; © 2013 American Cancer Society.

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21287" xmlns="http://purl.org/rss/1.0/"><title>uCyt+/ImmunoCyt and cytology in the detection of urothelial carcinoma</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21287</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">uCyt+/ImmunoCyt and cytology in the detection of urothelial carcinoma</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Evi Comploj, Christine Mian, Andrea Ambrosini-Spaltro, Christopher Dechet, Salvatore Palermo, Emanuela Trenti, Michele Lodde, Wolfgang Horninger, Armin Pycha</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-03-12T11:54:16.118248-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/cncy.21287</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/cncy.21287</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21287</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<div class="section" id="cncy21287-sec-0001" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib" xmlns="http://www.w3.org/1999/xhtml"><h4>BACKGROUND</h4><div class="para"><p>The aim of the current study was to report the results of 7422 uCyt+/ImmunoCyt and cytology analyses that were performed over the course of 9 years at the study institution for the evaluation and follow-up of patients with urothelial carcinoma.</p></div></div>
<div class="section" id="cncy21287-sec-0002" xmlns="http://www.w3.org/1999/xhtml"><h4>METHODS</h4><div class="para"><p>Between January 2002 and March 2011, 2217 patients with a mean age of 69.5 years (range, 15 years-99 years) were enrolled in the current study. All patients seen for the follow-up of bladder and/or upper tract urothelial cancer as well as those with a history that was suspicious for bladder cancer were recruited. In all patients, a voided urinary cytology and uCyt+/ImmunoCyt test was performed. Patients underwent routine cystoscopy as well as cystoscopy when cytology and/or the uCyt+/ImmunoCyt test yielded positive results. Lesions that were detected cystoscopically were biopsied and removed transurethrally. A total of 7422 uCyt+/ImmunoCyt and cytology analyses were performed.</p></div></div>
<div class="section" id="cncy21287-sec-0003" xmlns="http://www.w3.org/1999/xhtml"><h4>RESULTS</h4><div class="para"><p>Of the 7422 uCyt+/ImmunoCyt tests and cytologies that were performed, 7075 (95.3%) were considered adequate. A total of 578 patients (with 1156 analyses) underwent biopsy and 728 (63%) samples had a histologically proven urothelial carcinoma. Overall sensitivity was 34.5% for cytology, 68.1% for uCyt+/ImmunoCyt, and 72.8% for the 2 tests combined. Overall specificity was 97.9% for cytology, 72.3% for uCyt+/ImmunoCyt, and 71.9% for the 2 tests combined. Cytology and the uCyt+/ImmunoCyt test together had an overall sensitivity of 72.8%, with 59% for grade 1, 77% for grade 2, and 90% for grade 3 tumors (according to the 1973 World Health Organization grading classification system).</p></div></div>
<div class="section" id="cncy21287-sec-0004" xmlns="http://www.w3.org/1999/xhtml"><h4>CONCLUSIONS</h4><div class="para"><p>On the basis of their 9-year experience, the authors confirm the value of uCyt+/ImmunoCyt and cytology analyses in the follow-up of patients with non–muscle-invasive urothelial cancer. This could potentially reduce the number and cost of routine cystoscopic examinations in patients who are followed for bladder carcinoma. <b><em>Cancer (Cancer Cytopathol)</em> 2013;</b> © <em>2013 American Cancer Society</em>.</p></div></div>
]]></content:encoded><description>

BACKGROUND
The aim of the current study was to report the results of 7422 uCyt+/ImmunoCyt and cytology analyses that were performed over the course of 9 years at the study institution for the evaluation and follow-up of patients with urothelial carcinoma.


METHODS
Between January 2002 and March 2011, 2217 patients with a mean age of 69.5 years (range, 15 years-99 years) were enrolled in the current study. All patients seen for the follow-up of bladder and/or upper tract urothelial cancer as well as those with a history that was suspicious for bladder cancer were recruited. In all patients, a voided urinary cytology and uCyt+/ImmunoCyt test was performed. Patients underwent routine cystoscopy as well as cystoscopy when cytology and/or the uCyt+/ImmunoCyt test yielded positive results. Lesions that were detected cystoscopically were biopsied and removed transurethrally. A total of 7422 uCyt+/ImmunoCyt and cytology analyses were performed.


RESULTS
Of the 7422 uCyt+/ImmunoCyt tests and cytologies that were performed, 7075 (95.3%) were considered adequate. A total of 578 patients (with 1156 analyses) underwent biopsy and 728 (63%) samples had a histologically proven urothelial carcinoma. Overall sensitivity was 34.5% for cytology, 68.1% for uCyt+/ImmunoCyt, and 72.8% for the 2 tests combined. Overall specificity was 97.9% for cytology, 72.3% for uCyt+/ImmunoCyt, and 71.9% for the 2 tests combined. Cytology and the uCyt+/ImmunoCyt test together had an overall sensitivity of 72.8%, with 59% for grade 1, 77% for grade 2, and 90% for grade 3 tumors (according to the 1973 World Health Organization grading classification system).


CONCLUSIONS
On the basis of their 9-year experience, the authors confirm the value of uCyt+/ImmunoCyt and cytology analyses in the follow-up of patients with non–muscle-invasive urothelial cancer. This could potentially reduce the number and cost of routine cystoscopic examinations in patients who are followed for bladder carcinoma. Cancer (Cancer Cytopathol) 2013; © 2013 American Cancer Society.

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21285" xmlns="http://purl.org/rss/1.0/"><title>Thyroglobulin measurements in fine-needle aspiration cytology of lymph nodes for the detection of metastatic papillary thyroid carcinoma</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21285</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Thyroglobulin measurements in fine-needle aspiration cytology of lymph nodes for the detection of metastatic papillary thyroid carcinoma</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Qing Kay Li, Summer L. Nugent, Joely Straseski, David Cooper, Stefan Riedel, Frederic B. Askin, Lori J. Sokoll</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-03-12T11:36:48.929829-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/cncy.21285</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/cncy.21285</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21285</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<div class="section" id="cncy21285-sec-0001" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib" xmlns="http://www.w3.org/1999/xhtml"><h4>BACKGROUND</h4><div class="para"><p>Ultrasound-guided fine-needle aspiration (US-FNA) cytology is a commonly used method in the surveillance of suspicious lymph nodes (LNs) in patients with papillary thyroid carcinoma (PTC). The measurement of thyroglobulin (Tg) levels in LNs during FNA has been suggested to improve the diagnosis. In the current study, the use of US-FNA-Tg in LNs that were suspicious for metastatic PTC was investigated.</p></div></div>
<div class="section" id="cncy21285-sec-0002" xmlns="http://www.w3.org/1999/xhtml"><h4>METHODS</h4><div class="para"><p>A total of 208 cases from the Johns Hopkins Hospital with both US-guided FNA cytology and US-FNA-Tg measurements were included; 60 cases had follow-up surgeries performed. Tg levels were correlated with cytological and histological diagnoses.</p></div></div>
<div class="section" id="cncy21285-sec-0003" xmlns="http://www.w3.org/1999/xhtml"><h4>RESULTS</h4><div class="para"><p>Of 35 cases of cytologically diagnosed metastatic PTC, 34 were confirmed by surgery. The median US-FNA-Tg concentration was 4232.7 ng/mL, whereas in 112 benign LNs the median Tg concentration was &lt; 0.2 ng/mL (<em>P</em> &lt; .0001). Receiver operating characteristic analysis (area under the curve, 0.949) demonstrated a sensitivity of 97% and a specificity of 81% at the Tg detection limit (&lt;0.2 ng/mL), whereas cutoff values of 9.6 ng/mL to 100 ng/mL resulted in a sensitivity of 76% and a specificity of 98%. Of 15 cases with a cytological diagnosis of “suspicious for PTC,” 9 cases had markedly elevated Tg levels detected on FNA. Seven of these 9 cases had follow-up surgeries confirming the diagnosis of PTC. Of 29 cases with a “nondiagnostic” cytology, 7 had markedly elevated Tg levels on FNA, with a median of 1305.5 ng/mL, and were confirmed to be metastatic PTC at surgery.</p></div></div>
<div class="section" id="cncy21285-sec-0004" xmlns="http://www.w3.org/1999/xhtml"><h4>CONCLUSIONS</h4><div class="para"><p>US-FNA-Tg demonstrated a strong negative predictive value (93%-99%). It may be particularly useful for difficult cases. However, standardization of the sample collection is still needed to further improve the accuracy of the approach. <b><em>Cancer (Cancer Cytopathol)</em> 2013;</b> © <em>2013 American Cancer Society</em>.</p></div></div>
]]></content:encoded><description>

BACKGROUND
Ultrasound-guided fine-needle aspiration (US-FNA) cytology is a commonly used method in the surveillance of suspicious lymph nodes (LNs) in patients with papillary thyroid carcinoma (PTC). The measurement of thyroglobulin (Tg) levels in LNs during FNA has been suggested to improve the diagnosis. In the current study, the use of US-FNA-Tg in LNs that were suspicious for metastatic PTC was investigated.


METHODS
A total of 208 cases from the Johns Hopkins Hospital with both US-guided FNA cytology and US-FNA-Tg measurements were included; 60 cases had follow-up surgeries performed. Tg levels were correlated with cytological and histological diagnoses.


RESULTS
Of 35 cases of cytologically diagnosed metastatic PTC, 34 were confirmed by surgery. The median US-FNA-Tg concentration was 4232.7 ng/mL, whereas in 112 benign LNs the median Tg concentration was &lt; 0.2 ng/mL (P &lt; .0001). Receiver operating characteristic analysis (area under the curve, 0.949) demonstrated a sensitivity of 97% and a specificity of 81% at the Tg detection limit (&lt;0.2 ng/mL), whereas cutoff values of 9.6 ng/mL to 100 ng/mL resulted in a sensitivity of 76% and a specificity of 98%. Of 15 cases with a cytological diagnosis of “suspicious for PTC,” 9 cases had markedly elevated Tg levels detected on FNA. Seven of these 9 cases had follow-up surgeries confirming the diagnosis of PTC. Of 29 cases with a “nondiagnostic” cytology, 7 had markedly elevated Tg levels on FNA, with a median of 1305.5 ng/mL, and were confirmed to be metastatic PTC at surgery.


CONCLUSIONS
US-FNA-Tg demonstrated a strong negative predictive value (93%-99%). It may be particularly useful for difficult cases. However, standardization of the sample collection is still needed to further improve the accuracy of the approach. Cancer (Cancer Cytopathol) 2013; © 2013 American Cancer Society.

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21269" xmlns="http://purl.org/rss/1.0/"><title>Morphology of 9p21 homozygous deletion-positive pleural mesothelioma cells analyzed using fluorescence in situ hybridization and virtual microscope system in effusion cytology</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21269</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Morphology of 9p21 homozygous deletion-positive pleural mesothelioma cells analyzed using fluorescence in situ hybridization and virtual microscope system in effusion cytology</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Shinji Matsumoto, Kazuki Nabeshima, Toshiaki Kamei, Kenzo Hiroshima, Kunimitsu Kawahara, Sakae Hata, Katsuji Marukawa, Yoshihiro Matsuno, Kenichi Taguchi, Tohru Tsujimura</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-02-28T10:25:36.544398-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/cncy.21269</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/cncy.21269</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21269</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<div class="section" id="cncy21269-sec-0001" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib" xmlns="http://www.w3.org/1999/xhtml"><h4>BACKGROUND</h4><div class="para"><p>In malignant pleural mesothelioma (MPM), most patients first present with pleural effusion; thus, cytologic analysis is the primary diagnostic approach. However, the cytologic distinction between MPM and reactive mesothelial cells (RMCs) in effusions can be extremely difficult due to the lack of both well-established immunocytochemical markers and definite cytological criteria for MPM. Moreover, the existence of both MPM cells and RMCs in effusions from the same patient makes the differentiation even more challenging. Homozygous deletion of the 9p21 locus, the site of the cyclin-dependent kinase inhibitor 2A/p16 (<em>CDKN2A/p16</em>) gene, frequently occurs in MPM but has never been reported in RMCs. The aim of this study was to define the cytomorphological characteristics of MPM cells, identified by the presence of 9p21 homozygous deletion by fluorescence in situ hybridization (FISH).</p></div></div>
<div class="section" id="cncy21269-sec-0002" xmlns="http://www.w3.org/1999/xhtml"><h4>METHODS</h4><div class="para"><p>For this purpose, cells on smear preparations were recorded using a virtual microscope system and were subjected to FISH analysis. Thereafter, 9p21 homozygous deletion-positive cells were identified in the recorded virtual slides, followed by analysis of their morphological characteristics.</p></div></div>
<div class="section" id="cncy21269-sec-0003" xmlns="http://www.w3.org/1999/xhtml"><h4>RESULTS</h4><div class="para"><p>Mesothelioma cells positive for the 9p21 homozygous deletion exhibited significantly more frequent cell-in-cell engulfment, multinucleation (more than 2 nuclei), and larger multicellular clusters composed of more than 10 cells than did 9p21 deletion-negative RMCs. Possible cutoff values are also proposed for these morphological markers to differentiate MPM cells from RMCs.</p></div></div>
<div class="section" id="cncy21269-sec-0004" xmlns="http://www.w3.org/1999/xhtml"><h4>CONCLUSIONS</h4><div class="para"><p>These morphological differences and cutoff values are useful for cytological differentiation of mesothelioma cells from RMCs. In addition, the novel technique of a combination of virtual microscopy and FISH is introduced for tumor morphological analysis. Cancer (Cancer Cytopathol) 2013. © 2013 American Cancer Society.</p></div></div>
]]></content:encoded><description>

BACKGROUND
In malignant pleural mesothelioma (MPM), most patients first present with pleural effusion; thus, cytologic analysis is the primary diagnostic approach. However, the cytologic distinction between MPM and reactive mesothelial cells (RMCs) in effusions can be extremely difficult due to the lack of both well-established immunocytochemical markers and definite cytological criteria for MPM. Moreover, the existence of both MPM cells and RMCs in effusions from the same patient makes the differentiation even more challenging. Homozygous deletion of the 9p21 locus, the site of the cyclin-dependent kinase inhibitor 2A/p16 (CDKN2A/p16) gene, frequently occurs in MPM but has never been reported in RMCs. The aim of this study was to define the cytomorphological characteristics of MPM cells, identified by the presence of 9p21 homozygous deletion by fluorescence in situ hybridization (FISH).


METHODS
For this purpose, cells on smear preparations were recorded using a virtual microscope system and were subjected to FISH analysis. Thereafter, 9p21 homozygous deletion-positive cells were identified in the recorded virtual slides, followed by analysis of their morphological characteristics.


RESULTS
Mesothelioma cells positive for the 9p21 homozygous deletion exhibited significantly more frequent cell-in-cell engulfment, multinucleation (more than 2 nuclei), and larger multicellular clusters composed of more than 10 cells than did 9p21 deletion-negative RMCs. Possible cutoff values are also proposed for these morphological markers to differentiate MPM cells from RMCs.


CONCLUSIONS
These morphological differences and cutoff values are useful for cytological differentiation of mesothelioma cells from RMCs. In addition, the novel technique of a combination of virtual microscopy and FISH is introduced for tumor morphological analysis. Cancer (Cancer Cytopathol) 2013. © 2013 American Cancer Society.

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21274" xmlns="http://purl.org/rss/1.0/"><title>Should high-risk adolescents have Papanicolaou tests?</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21274</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Should high-risk adolescents have Papanicolaou tests?</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Ly T. Ma, Gerald A. Campbell, Gwyn Richardson, Vicki J. Schnadig</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-02-28T10:25:21.735411-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/cncy.21274</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/cncy.21274</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21274</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<div class="section" id="cncy21274-sec-0001" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib" xmlns="http://www.w3.org/1999/xhtml"><h4>BACKGROUND</h4><div class="para"><p>The current American College of Obstetricians and Gynecologists guidelines state that cervical cancer screening should begin at age 21 years, regardless of sexual or obstetric history. However, previous studies have demonstrated that there is a small but significant subset of high-risk adolescents with extensive sexual and obstetric history who harbor a significant squamous cervical lesion. The objective of the current study was to use histologic and demographic data from adolescents (aged &lt;21 years) who received Papanicolaou (Pap) tests to determine whether they benefited from early cervical cancer screening.</p></div></div>
<div class="section" id="cncy21274-sec-0002" xmlns="http://www.w3.org/1999/xhtml"><h4>METHODS</h4><div class="para"><p>Adolescent girls who had Pap tests between 2000 and 2010 were included in the study. Demographic data, including obstetric history, number of sexual partners, age of first coitus, age at first pregnancy, menarche, smoking history, and Chlamydia and syphilis infection, were analyzed for associations with levels of cervical dysplasia.</p></div></div>
<div class="section" id="cncy21274-sec-0003" xmlns="http://www.w3.org/1999/xhtml"><h4>RESULTS</h4><div class="para"><p>Of 56,785 adolescent Pap tests, 277 (0.5%) were diagnosed as high-grade squamous HSIL, and 56 of those Pap tests (20%) were from patients who had grade 3 cervical intraepithelial neoplasia (CIN-3) on subsequent biopsy and/or excision. One patient had microinvasive cervical carcinoma identified on loop electrosurgical excision procedure at age 27 years after an HSIL Pap test. Increased parity was associated significantly with higher rates of CIN-3.</p></div></div>
<div class="section" id="cncy21274-sec-0004" xmlns="http://www.w3.org/1999/xhtml"><h4>CONCLUSIONS</h4><div class="para"><p>The study findings indicated that current American College of Obstetricians and Gynecologists guidelines to begin Pap testing at age 21 years are appropriate for the majority of adolescents, because the rate of HSIL is very low, and the risk for invasive carcinoma is minimal. Although higher parity was associated with a significantly increased grade of CIN, the conclusions are questionable because of the significant amount of missing demographic data points. That being said, this study should lead to other similar studies to determine any association of higher grade CIN with adolescent sexual and obstetric history. Cancer (Cancer Cytopathol) 2013. © 2012 American Cancer Society.</p></div></div>
]]></content:encoded><description>

BACKGROUND
The current American College of Obstetricians and Gynecologists guidelines state that cervical cancer screening should begin at age 21 years, regardless of sexual or obstetric history. However, previous studies have demonstrated that there is a small but significant subset of high-risk adolescents with extensive sexual and obstetric history who harbor a significant squamous cervical lesion. The objective of the current study was to use histologic and demographic data from adolescents (aged &lt;21 years) who received Papanicolaou (Pap) tests to determine whether they benefited from early cervical cancer screening.


METHODS
Adolescent girls who had Pap tests between 2000 and 2010 were included in the study. Demographic data, including obstetric history, number of sexual partners, age of first coitus, age at first pregnancy, menarche, smoking history, and Chlamydia and syphilis infection, were analyzed for associations with levels of cervical dysplasia.


RESULTS
Of 56,785 adolescent Pap tests, 277 (0.5%) were diagnosed as high-grade squamous HSIL, and 56 of those Pap tests (20%) were from patients who had grade 3 cervical intraepithelial neoplasia (CIN-3) on subsequent biopsy and/or excision. One patient had microinvasive cervical carcinoma identified on loop electrosurgical excision procedure at age 27 years after an HSIL Pap test. Increased parity was associated significantly with higher rates of CIN-3.


CONCLUSIONS
The study findings indicated that current American College of Obstetricians and Gynecologists guidelines to begin Pap testing at age 21 years are appropriate for the majority of adolescents, because the rate of HSIL is very low, and the risk for invasive carcinoma is minimal. Although higher parity was associated with a significantly increased grade of CIN, the conclusions are questionable because of the significant amount of missing demographic data points. That being said, this study should lead to other similar studies to determine any association of higher grade CIN with adolescent sexual and obstetric history. Cancer (Cancer Cytopathol) 2013. © 2012 American Cancer Society.

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21283" xmlns="http://purl.org/rss/1.0/"><title>Diagnostic value of tumor markers in lung adenocarcinoma-associated cytologically negative pleural effusions</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21283</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Diagnostic value of tumor markers in lung adenocarcinoma-associated cytologically negative pleural effusions</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Tsung-Cheng Hsieh, Wen-Wei Huang, Chun-Liang Lai, Shih-Ming Tsao, Cheng-Chuan Su</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-02-13T11:48:38.434624-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/cncy.21283</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/cncy.21283</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21283</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<div class="section" id="cncy21283-sec-0001" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib" xmlns="http://www.w3.org/1999/xhtml"><h4>BACKGROUND</h4><div class="para"><p>Cytology fails to detect neoplastic cells in approximately 40% to 50% of malignant pleural effusions (PEs), which commonly accompany lung adenocarcinomas. The diagnostic accuracy of various tumor markers in lung adenocarcinoma-associated cytologically negative pleural effusions (LAC-CNPEs) has been poor. The current study attempted to maximize diagnostic efforts in distinguishing LAC-CNPEs from benign PEs.</p></div></div>
<div class="section" id="cncy21283-sec-0002" xmlns="http://www.w3.org/1999/xhtml"><h4>METHODS</h4><div class="para"><p>PE samples were collected from 74 patients with lung adenocarcinoma with associated cytologically positive (41 patients) and negative (33 patients) PEs, and from 99 patients with benign conditions including tuberculosis (26 patients), pneumonia (28 patients), congestive heart failure (25 patients), and cirrhosis (20 patients). The authors evaluated the diagnostic sensitivity and optimal cutoff points for the tumor markers HER2/neu, CYFRA 21-1, and carcinoembryonic antigen (CEA) to distinguish LAC-CNPEs from benign PEs.</p></div></div>
<div class="section" id="cncy21283-sec-0003" xmlns="http://www.w3.org/1999/xhtml"><h4>RESULTS</h4><div class="para"><p>Mean levels of HER2/neu, CYRFA 21-1, and CEA were found to be significantly higher in LAC-CNPEs compared with benign PEs (<em>P</em> = .0050, <em>P</em> = .0039, and P &lt; .0001, respectively). The cutoff points for HER2/neu, CYFRA 21-1, and CEA were optimally set at 3.6 ng/mL, 60 ng/mL, and 6.0 ng/mL, respectively. Their sensitivities ranged from 12.1%, to 30.3%, to 63.6%, respectively. CEA combined with CYFRA 21-1 increased diagnostic sensitivity to 66.7%. The false-positive rates of these markers in benign PEs were 6.1%, 2.0%, and 0%, respectively.</p></div></div>
<div class="section" id="cncy21283-sec-0004" xmlns="http://www.w3.org/1999/xhtml"><h4>CONCLUSIONS</h4><div class="para"><p>The combination of CEA with CYFRA 21-1 appears to provide the best differentiation between LAC-CNPEs and benign PEs to date using 2 tumor markers, and allows for the early diagnosis and early treatment of approximately two-thirds of affected patients. <b><em>Cancer (Cancer Cytopathol)</em> 2013;.</b> © <em>2013 American Cancer Society</em>.</p></div></div>
]]></content:encoded><description>

BACKGROUND
Cytology fails to detect neoplastic cells in approximately 40% to 50% of malignant pleural effusions (PEs), which commonly accompany lung adenocarcinomas. The diagnostic accuracy of various tumor markers in lung adenocarcinoma-associated cytologically negative pleural effusions (LAC-CNPEs) has been poor. The current study attempted to maximize diagnostic efforts in distinguishing LAC-CNPEs from benign PEs.


METHODS
PE samples were collected from 74 patients with lung adenocarcinoma with associated cytologically positive (41 patients) and negative (33 patients) PEs, and from 99 patients with benign conditions including tuberculosis (26 patients), pneumonia (28 patients), congestive heart failure (25 patients), and cirrhosis (20 patients). The authors evaluated the diagnostic sensitivity and optimal cutoff points for the tumor markers HER2/neu, CYFRA 21-1, and carcinoembryonic antigen (CEA) to distinguish LAC-CNPEs from benign PEs.


RESULTS
Mean levels of HER2/neu, CYRFA 21-1, and CEA were found to be significantly higher in LAC-CNPEs compared with benign PEs (P = .0050, P = .0039, and P &lt; .0001, respectively). The cutoff points for HER2/neu, CYFRA 21-1, and CEA were optimally set at 3.6 ng/mL, 60 ng/mL, and 6.0 ng/mL, respectively. Their sensitivities ranged from 12.1%, to 30.3%, to 63.6%, respectively. CEA combined with CYFRA 21-1 increased diagnostic sensitivity to 66.7%. The false-positive rates of these markers in benign PEs were 6.1%, 2.0%, and 0%, respectively.


CONCLUSIONS
The combination of CEA with CYFRA 21-1 appears to provide the best differentiation between LAC-CNPEs and benign PEs to date using 2 tumor markers, and allows for the early diagnosis and early treatment of approximately two-thirds of affected patients. Cancer (Cancer Cytopathol) 2013;. © 2013 American Cancer Society.

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21281" xmlns="http://purl.org/rss/1.0/"><title>Detection of EGFR mutations and EML4-ALK rearrangements in lung adenocarcinomas using archived cytological slides</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21281</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Detection of EGFR mutations and EML4-ALK rearrangements in lung adenocarcinomas using archived cytological slides</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Natalia V. Mitiushkina, Aglaya G. Iyevleva, Artiom N. Poltoratskiy, Alexandr O. Ivantsov, Alexandr V. Togo, Igor S. Polyakov, Sergey V. Orlov, Dmitry E. Matsko, Viktor I. Novik, Evgeny N. Imyanitov</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-02-13T11:48:32.515387-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/cncy.21281</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/cncy.21281</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21281</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<div class="section" id="cncy21281-sec-0001" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib" xmlns="http://www.w3.org/1999/xhtml"><h4>BACKGROUND</h4><div class="para"><p>Although the molecular analysis of epidermal growth factor receptor (<em>EGFR)</em> and anaplastic lymphoma kinase (<em>ALK</em>) in archived lung cancer tissues is relatively well established, the genetic testing of cytological material has not yet become a routine.</p></div></div>
<div class="section" id="cncy21281-sec-0002" xmlns="http://www.w3.org/1999/xhtml"><h4>METHODS</h4><div class="para"><p>The current study used cell samples that were obtained by bronchial brushing, transthoracic needle aspiration, or biopsy imprint preparation between 1993 and 2008. Islets of malignant cells were visually located on the archived cytological slides, lysed in situ by a drop of sodium dodecyl sulfate-containing buffer, and subjected to the standard DNA and RNA extraction. Examination of paraffin-embedded tissue blocks (resection specimens or biopsy material) from the same patients was performed in parallel.</p></div></div>
<div class="section" id="cncy21281-sec-0003" xmlns="http://www.w3.org/1999/xhtml"><h4>RESULTS</h4><div class="para"><p>A total of 75 cytological/histological lung adenocarcinoma sample pairs underwent polymerase chain reaction analysis for the <em>EGFR</em> mutation. Two cytological samples and 1 morphological sample failed to produce DNA. Concordance for the wild-type and mutation status was observed in 54 of 72 and 14 of 72 informative pairs, respectively; 3 pairs and 1 pair, respectively, had mutation only in the cytological or histological material. The discrepancies could be explained by the failure to ensure a high percentage of lung cancer cells in the analyzed samples or, alternatively, by the genuine intratumoral molecular heterogeneity of some neoplasms. RNA extraction followed by reverse transcriptase-polymerase chain reaction analysis for the <em>EML4</em>-<em>ALK</em> translocation was performed for 44 <em>EGFR</em> mutation-negative sample pairs; failures were observed for 2 cytological and 6 histological specimens. All informative pairs were concordant either for the norm (32 of 36 pairs) or for the presence of <em>EML4-ALK</em> gene fusion (4 of 36 pairs).</p></div></div>
<div class="section" id="cncy21281-sec-0004" xmlns="http://www.w3.org/1999/xhtml"><h4>CONCLUSIONS</h4><div class="para"><p>Archived cytological slides appear to be well suited both for <em>EGFR</em> and <em>ALK</em> analysis. <b><em>Cancer (Cancer Cytopathol)</em> 2013;</b> © <em>2013 American Cancer Society</em>.</p></div></div>
]]></content:encoded><description>

BACKGROUND
Although the molecular analysis of epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) in archived lung cancer tissues is relatively well established, the genetic testing of cytological material has not yet become a routine.


METHODS
The current study used cell samples that were obtained by bronchial brushing, transthoracic needle aspiration, or biopsy imprint preparation between 1993 and 2008. Islets of malignant cells were visually located on the archived cytological slides, lysed in situ by a drop of sodium dodecyl sulfate-containing buffer, and subjected to the standard DNA and RNA extraction. Examination of paraffin-embedded tissue blocks (resection specimens or biopsy material) from the same patients was performed in parallel.


RESULTS
A total of 75 cytological/histological lung adenocarcinoma sample pairs underwent polymerase chain reaction analysis for the EGFR mutation. Two cytological samples and 1 morphological sample failed to produce DNA. Concordance for the wild-type and mutation status was observed in 54 of 72 and 14 of 72 informative pairs, respectively; 3 pairs and 1 pair, respectively, had mutation only in the cytological or histological material. The discrepancies could be explained by the failure to ensure a high percentage of lung cancer cells in the analyzed samples or, alternatively, by the genuine intratumoral molecular heterogeneity of some neoplasms. RNA extraction followed by reverse transcriptase-polymerase chain reaction analysis for the EML4-ALK translocation was performed for 44 EGFR mutation-negative sample pairs; failures were observed for 2 cytological and 6 histological specimens. All informative pairs were concordant either for the norm (32 of 36 pairs) or for the presence of EML4-ALK gene fusion (4 of 36 pairs).


CONCLUSIONS
Archived cytological slides appear to be well suited both for EGFR and ALK analysis. Cancer (Cancer Cytopathol) 2013; © 2013 American Cancer Society.

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21279" xmlns="http://purl.org/rss/1.0/"><title>Cytomorphologic and immunophenotypical features of acinar cell neoplasms of the pancreas</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21279</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Cytomorphologic and immunophenotypical features of acinar cell neoplasms of the pancreas</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Carlie S. Sigel, David S. Klimstra</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-02-13T11:48:20.719873-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/cncy.21279</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/cncy.21279</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21279</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<div class="section" id="cncy21279-sec-0001" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib" xmlns="http://www.w3.org/1999/xhtml"><h4>BACKGROUND</h4><div class="para"><p>Acinar cell neoplasms of the pancreas are rare but when encountered, the diagnosis is often established based on cytology specimens. Diagnostic accuracy is important because acinar cell carcinomas are aggressive yet may mimic tumors with different outcomes and management.</p></div></div>
<div class="section" id="cncy21279-sec-0002" xmlns="http://www.w3.org/1999/xhtml"><h4>METHODS</h4><div class="para"><p>The authors identified all patients with a diagnosis of acinar cell neoplasm in the institutional database; assessed cytomorphology and immunocytochemistry for trypsin, chymotrypsin, synaptophysin, chromogranin A, and MIB-1; and compared all cytology and final histological diagnoses for diagnostic discrepancies.</p></div></div>
<div class="section" id="cncy21279-sec-0003" xmlns="http://www.w3.org/1999/xhtml"><h4>RESULTS</h4><div class="para"><p>Cytological features were described for 16 histologically proven malignant acinar cell neoplasms: acinar cell carcinoma (8 cases), mixed acinar-neuroendocrine carcinoma (6 cases), mixed acinar-ductal carcinoma (1 case), and pancreatoblastoma (1 case).The majority of aspirates from acinar cell cystadenomas were nondiagnostic or negative (5 of 6 cases; 83%). Acinar and neuroendocrine differentiation that was detected by immunocytochemistry in &gt;20% of tumor cells was found to be correlated with mixed acinar-neuroendocrine carcinoma histology. Cytohistological correlation included 32 patients with 17 discordant diagnoses (53%). The following preoperative cytology diagnoses proved to be acinar cell neoplasms on resection: neuroendocrine tumor (5 cases), adenocarcinoma (5 cases), atypical ductal cells (2 cases), solid pseudopapillary neoplasm, and hepatocellular carcinoma. Three aspirates diagnosed as acinar cell carcinoma by cytology proved to be chronic pancreatitis (2 cases) and ductal adenocarcinoma (1 case).</p></div></div>
<div class="section" id="cncy21279-sec-0004" xmlns="http://www.w3.org/1999/xhtml"><h4>CONCLUSIONS</h4><div class="para"><p>Acinar cell carcinoma has a distinctive cytological appearance but is frequently misdiagnosed on cytology. Immunocytochemistry is useful for identifying acinar differentiation. Cancer (Cancer Cytopathol) 2013. © 2013 American Cancer Society.</p></div></div>
]]></content:encoded><description>

BACKGROUND
Acinar cell neoplasms of the pancreas are rare but when encountered, the diagnosis is often established based on cytology specimens. Diagnostic accuracy is important because acinar cell carcinomas are aggressive yet may mimic tumors with different outcomes and management.


METHODS
The authors identified all patients with a diagnosis of acinar cell neoplasm in the institutional database; assessed cytomorphology and immunocytochemistry for trypsin, chymotrypsin, synaptophysin, chromogranin A, and MIB-1; and compared all cytology and final histological diagnoses for diagnostic discrepancies.


RESULTS
Cytological features were described for 16 histologically proven malignant acinar cell neoplasms: acinar cell carcinoma (8 cases), mixed acinar-neuroendocrine carcinoma (6 cases), mixed acinar-ductal carcinoma (1 case), and pancreatoblastoma (1 case).The majority of aspirates from acinar cell cystadenomas were nondiagnostic or negative (5 of 6 cases; 83%). Acinar and neuroendocrine differentiation that was detected by immunocytochemistry in &gt;20% of tumor cells was found to be correlated with mixed acinar-neuroendocrine carcinoma histology. Cytohistological correlation included 32 patients with 17 discordant diagnoses (53%). The following preoperative cytology diagnoses proved to be acinar cell neoplasms on resection: neuroendocrine tumor (5 cases), adenocarcinoma (5 cases), atypical ductal cells (2 cases), solid pseudopapillary neoplasm, and hepatocellular carcinoma. Three aspirates diagnosed as acinar cell carcinoma by cytology proved to be chronic pancreatitis (2 cases) and ductal adenocarcinoma (1 case).


CONCLUSIONS
Acinar cell carcinoma has a distinctive cytological appearance but is frequently misdiagnosed on cytology. Immunocytochemistry is useful for identifying acinar differentiation. Cancer (Cancer Cytopathol) 2013. © 2013 American Cancer Society.

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21276" xmlns="http://purl.org/rss/1.0/"><title>Preparation of DNA from cytological material</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21276</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Preparation of DNA from cytological material</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Annika Dejmek, Nooreldin Zendehrokh, Malgorzata Tomaszewska, Anders Edsjö</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-02-13T11:48:02.51407-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/cncy.21276</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/cncy.21276</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21276</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<div class="section" id="cncy21276-sec-0001" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib" xmlns="http://www.w3.org/1999/xhtml"><h4>BACKGROUND</h4><div class="para"><p>Personalized oncology requires molecular analysis of tumor cells. Several studies have demonstrated that cytological material is suitable for DNA analysis, but to the authors' knowledge there are no systematic studies comparing how the yield and quality of extracted DNA is affected by the various techniques used for the preparation of cytological material.</p></div></div>
<div class="section" id="cncy21276-sec-0002" xmlns="http://www.w3.org/1999/xhtml"><h4>METHODS</h4><div class="para"><p>DNA yield and quality were compared using cultured human lung cancer cells subjected to different preparation techniques used in routine cytology, including fixation, mounting medium, and staining. The results were compared with the outcome of epidermal growth factor receptor (<em>EGFR</em>) genotyping of 66 clinical cytological samples using the same DNA preparation protocol.</p></div></div>
<div class="section" id="cncy21276-sec-0003" xmlns="http://www.w3.org/1999/xhtml"><h4>RESULTS</h4><div class="para"><p>All tested protocol combinations resulted in fragment lengths of at least 388 base pairs. The mounting agent EcoMount resulted in higher yields than traditional xylene-based medium. Spray and ethanol fixation resulted in both a higher yield and better DNA quality than air drying. In liquid-based cytology (LBC) methods, CytoLyt solution resulted in a 5-fold higher yield than CytoRich Red. Papanicolaou staining provided twice the yield of hematoxylin and eosin staining in both liquid-based preparations. Genotyping outcome and quality control values from the clinical <em>EGFR</em> genotyping demonstrated a sufficient amount and amplifiability of DNA in both spray-fixed and air-dried cytological samples.</p></div></div>
<div class="section" id="cncy21276-sec-0004" xmlns="http://www.w3.org/1999/xhtml"><h4>CONCLUSIONS</h4><div class="para"><p>Reliable clinical genotyping can be performed using all tested methods. However, in the cell line experiments, spray- or ethanol-fixed, Papanicolaou-stained slides provided the best results in terms of yield and fragment length. In LBC, the DNA recovery efficiency of the preserving medium may differ considerably, which should be taken into consideration when introducing LBC. Cancer (Cancer Cytopathol) 2013. © 2013 American Cancer Society.</p></div></div>
]]></content:encoded><description>

BACKGROUND
Personalized oncology requires molecular analysis of tumor cells. Several studies have demonstrated that cytological material is suitable for DNA analysis, but to the authors' knowledge there are no systematic studies comparing how the yield and quality of extracted DNA is affected by the various techniques used for the preparation of cytological material.


METHODS
DNA yield and quality were compared using cultured human lung cancer cells subjected to different preparation techniques used in routine cytology, including fixation, mounting medium, and staining. The results were compared with the outcome of epidermal growth factor receptor (EGFR) genotyping of 66 clinical cytological samples using the same DNA preparation protocol.


RESULTS
All tested protocol combinations resulted in fragment lengths of at least 388 base pairs. The mounting agent EcoMount resulted in higher yields than traditional xylene-based medium. Spray and ethanol fixation resulted in both a higher yield and better DNA quality than air drying. In liquid-based cytology (LBC) methods, CytoLyt solution resulted in a 5-fold higher yield than CytoRich Red. Papanicolaou staining provided twice the yield of hematoxylin and eosin staining in both liquid-based preparations. Genotyping outcome and quality control values from the clinical EGFR genotyping demonstrated a sufficient amount and amplifiability of DNA in both spray-fixed and air-dried cytological samples.


CONCLUSIONS
Reliable clinical genotyping can be performed using all tested methods. However, in the cell line experiments, spray- or ethanol-fixed, Papanicolaou-stained slides provided the best results in terms of yield and fragment length. In LBC, the DNA recovery efficiency of the preserving medium may differ considerably, which should be taken into consideration when introducing LBC. Cancer (Cancer Cytopathol) 2013. © 2013 American Cancer Society.

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21280" xmlns="http://purl.org/rss/1.0/"><title>Prediction of outcome in patients with low-grade squamous intraepithelial lesions by fluorescence in situ hybridization analysis of human papillomavirus, TERC, and MYC</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21280</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Prediction of outcome in patients with low-grade squamous intraepithelial lesions by fluorescence in situ hybridization analysis of human papillomavirus, TERC, and MYC</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Ellen C. Obermann, Spasenija Savic Prince, Audrey Barascud, Bruno Grilli, Michelle Herzog, Daniela Kaup, Gieri Cathomas, Brigitte Frey Tirri, Inti Zlobec, Edward Wight, Lukas Bubendorf</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-02-13T11:47:51.781025-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/cncy.21280</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/cncy.21280</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21280</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<div class="section" id="cncy21280-sec-0001" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib" xmlns="http://www.w3.org/1999/xhtml"><h4>BACKGROUND</h4><div class="para"><p>Cytology is an excellent method with which to diagnose preinvasive lesions of the uterine cervix, but it suffers from limited specificity for clinically significant lesions. Supplementary methods might predict the natural course of the detected lesions. The objective of the current study was to test whether a multicolor fluorescence in situ hybridization (FISH) assay might help to stratify abnormal results of Papanicolaou tests.</p></div></div>
<div class="section" id="cncy21280-sec-0002" xmlns="http://www.w3.org/1999/xhtml"><h4>METHODS</h4><div class="para"><p>A total of 219 liquid-based cytology specimens of low-grade squamous intraepithelial lesions (LSIL), 49 atypical squamous cells of undetermined significance (ASCUS) specimens, 52 high-grade squamous intraepithelial lesion (HSIL) specimens, and 50 normal samples were assessed by FISH with probes for the human papillomavirus (HPV), <em>MYC,</em> and telomerase RNA component (<em>TERC</em>). Subtyping of HPV by polymerase chain reaction (PCR) was performed in a subset of cases (n=206).</p></div></div>
<div class="section" id="cncy21280-sec-0003" xmlns="http://www.w3.org/1999/xhtml"><h4>RESULTS</h4><div class="para"><p>There was a significant correlation found between HPV detection by FISH and PCR (<em>P</em>&lt;.0001). In patients with LSILs, the presence of HPV detected by FISH was significantly associated with disease progression (<em>P</em>&lt;.0001). An increased <em>MYC</em> and/or <em>TERC</em> gene copy number (&gt;2 signals in&gt;10% of cells) prevailed in 43% of ASCUS specimens and was more frequent in HSIL (85%) than in LSIL (33%) (HSIL vs LSIL: <em>P</em>&lt;.0001). Increased <em>TERC</em> gene copy number was significantly correlated with progression of LSIL (<em>P</em>&lt;.01; odds ratio, 7.44; area under the receiver operating characteristic curve, 0.73; positive predictive value, 0.30; negative predictive value, 0.94)</p></div></div>
<div class="section" id="cncy21280-sec-0004" xmlns="http://www.w3.org/1999/xhtml"><h4>CONCLUSIONS</h4><div class="para"><p>The detection of HPV by FISH analysis is feasible in liquid-based cytology and is significantly correlated with HPV analysis by PCR. The analysis of <em>TERC</em> gene copy number may be useful for risk stratification in patients with LSIL. Cancer (Cancer Cytopathol) 2013. © 2013 American Cancer Society.</p></div></div>
]]></content:encoded><description>

BACKGROUND
Cytology is an excellent method with which to diagnose preinvasive lesions of the uterine cervix, but it suffers from limited specificity for clinically significant lesions. Supplementary methods might predict the natural course of the detected lesions. The objective of the current study was to test whether a multicolor fluorescence in situ hybridization (FISH) assay might help to stratify abnormal results of Papanicolaou tests.


METHODS
A total of 219 liquid-based cytology specimens of low-grade squamous intraepithelial lesions (LSIL), 49 atypical squamous cells of undetermined significance (ASCUS) specimens, 52 high-grade squamous intraepithelial lesion (HSIL) specimens, and 50 normal samples were assessed by FISH with probes for the human papillomavirus (HPV), MYC, and telomerase RNA component (TERC). Subtyping of HPV by polymerase chain reaction (PCR) was performed in a subset of cases (n=206).


RESULTS
There was a significant correlation found between HPV detection by FISH and PCR (P&lt;.0001). In patients with LSILs, the presence of HPV detected by FISH was significantly associated with disease progression (P&lt;.0001). An increased MYC and/or TERC gene copy number (&gt;2 signals in&gt;10% of cells) prevailed in 43% of ASCUS specimens and was more frequent in HSIL (85%) than in LSIL (33%) (HSIL vs LSIL: P&lt;.0001). Increased TERC gene copy number was significantly correlated with progression of LSIL (P&lt;.01; odds ratio, 7.44; area under the receiver operating characteristic curve, 0.73; positive predictive value, 0.30; negative predictive value, 0.94)


CONCLUSIONS
The detection of HPV by FISH analysis is feasible in liquid-based cytology and is significantly correlated with HPV analysis by PCR. The analysis of TERC gene copy number may be useful for risk stratification in patients with LSIL. Cancer (Cancer Cytopathol) 2013. © 2013 American Cancer Society.

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21272" xmlns="http://purl.org/rss/1.0/"><title>Cytologic and cystoscopic predictors of recurrence and progression in patients with low-grade urothelial carcinoma</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21272</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Cytologic and cystoscopic predictors of recurrence and progression in patients with low-grade urothelial carcinoma</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Julie Jackson, Güliz A. Barkan, Umesh Kapur, Eva M. Wojcik</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-01-30T11:04:03.016023-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/cncy.21272</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/cncy.21272</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21272</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>BACKGROUND:</h4><div class="para"><p>Patients with low-grade urothelial carcinoma (LGUC) are at risk of recurrence and must undergo lifelong surveillance. To date, cytology and cystoscopy are the gold standard for the detection of de novo and recurrent LGUC. The objective of the current study was is to further characterize the role of cytology and cystoscopy in determining the risk of recurrence and progression in these patients.</p></div></div>
<div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>METHODS:</h4><div class="para"><p>The authors retrospectively identified patients with LGUC who had urine cytology within 2 months of biopsy, and data were abstracted from their electronic charts. Electronic medical records were reviewed for cystoscopic findings and histologic and cytologic follow-up data over a 5-year period. Statistical analysis was performed with chi-square tests.</p></div></div>
<div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>RESULTS:</h4><div class="para"><p>In total, 76 patients were identified who had histologic follow-up material available, and 49% of those patients demonstrated progression or recurrence of urothelial carcinoma. The initial presence of multiple lesions on cystoscopy was associated with any recurrence or progression (67.7% vs 31%; <em>P</em> = .002), tumor size &gt;2 cm was associated with initial positive or suspicious urine cytology (23.8% vs 3.7%; <em>P</em> = .076), and positive or suspicious initial cytology was associated with high-grade recurrence (58.3% vs 19.4%; <em>P</em> = .009).</p></div></div>
<div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h4>CONCLUSIONS:</h4><div class="para"><p>Cystoscopic findings, such as the presence of multiple lesions, together with concurrent positive or suspicious urine cytology, were associated with recurrence or progression of LGUC. These findings may help to identify high-risk patients. Cancer (Cancer Cytopathol) 2012;. © 2012 American Cancer Society.</p></div></div>
]]></content:encoded><description>


BACKGROUND:
Patients with low-grade urothelial carcinoma (LGUC) are at risk of recurrence and must undergo lifelong surveillance. To date, cytology and cystoscopy are the gold standard for the detection of de novo and recurrent LGUC. The objective of the current study was is to further characterize the role of cytology and cystoscopy in determining the risk of recurrence and progression in these patients.


METHODS:
The authors retrospectively identified patients with LGUC who had urine cytology within 2 months of biopsy, and data were abstracted from their electronic charts. Electronic medical records were reviewed for cystoscopic findings and histologic and cytologic follow-up data over a 5-year period. Statistical analysis was performed with chi-square tests.


RESULTS:
In total, 76 patients were identified who had histologic follow-up material available, and 49% of those patients demonstrated progression or recurrence of urothelial carcinoma. The initial presence of multiple lesions on cystoscopy was associated with any recurrence or progression (67.7% vs 31%; P = .002), tumor size &gt;2 cm was associated with initial positive or suspicious urine cytology (23.8% vs 3.7%; P = .076), and positive or suspicious initial cytology was associated with high-grade recurrence (58.3% vs 19.4%; P = .009).


CONCLUSIONS:
Cystoscopic findings, such as the presence of multiple lesions, together with concurrent positive or suspicious urine cytology, were associated with recurrence or progression of LGUC. These findings may help to identify high-risk patients. Cancer (Cancer Cytopathol) 2012;. © 2012 American Cancer Society.

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21273" xmlns="http://purl.org/rss/1.0/"><title>Comparative study of epidermal growth factor receptor mutation analysis on cytology smears and surgical pathology specimens from primary and metastatic lung carcinomas</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21273</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Comparative study of epidermal growth factor receptor mutation analysis on cytology smears and surgical pathology specimens from primary and metastatic lung carcinomas</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Renu Khode, Douglas A. Larsen, Brianne C. Culbreath, Shane Parrish, Kimberly L. Walker, Lubna Sayage-Rabie, Robert S. Beissner, Arundhati Rao</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-01-30T11:03:49.224875-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/cncy.21273</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/cncy.21273</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21273</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>BACKGROUND:</h4><div class="para"><p>The detection of epidermal growth factor receptor (EGFR) mutations on small biopsy or fine-needle aspiration samples is required to guide therapy in nonsmall cell lung cancer (NSCLC). In this study, the authors compared results from EGFR mutation testing on both cytologic smears and surgical specimens and also compared the performance of platforms using 2 different technologies (pyrosequencing and real-time polymerase chain reaction) for both specimen types.</p></div></div>
<div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>METHODS:</h4><div class="para"><p>Specimens from 114 patients were divided into 2 subsets. The first subset had 60 paired cytology smears and surgical specimens, including 37 paired specimens from the same site and 23 paired specimens from different sites. The second subset consisted of nonpaired cytology smears and formalin-fixed, paraffin-embedded (FFPE) tissues (including 8 cell blocks), which were compared on the pyrosequencing and real-time polymerase chain reaction platforms. Laser-capture microscopy was used to enrich tumor in the FFPE specimens before DNA extraction.</p></div></div>
<div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>RESULTS:</h4><div class="para"><p>All cytology smears that were used in the study were adequate for analysis on both platforms. Comparison between smears and concurrent FFPE tissues from the same anatomic site had a concordance rate of 97%. The concordance rate between the pyrosequencing platform and the real-time polymerase chain reaction platform was 84% and 85% for FFPE tissues and cytology smears, respectively.</p></div></div>
<div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h4>CONCLUSIONS:</h4><div class="para"><p>The current results indicated that direct extraction and analysis of EGFR mutations from cytology smears can be performed successfully on both a pyrosequencing platform and a real-time polymerase chain reaction platform with results comparable to those achieved in matched surgical specimens. In fine-needle aspiration/endobronchial ultrasound samples with limited tissue, cytology smears can be important for molecular analysis. Cancer (Cancer Cytopathol) 2013;. © 2012 American Cancer Society.</p></div></div>
]]></content:encoded><description>


BACKGROUND:
The detection of epidermal growth factor receptor (EGFR) mutations on small biopsy or fine-needle aspiration samples is required to guide therapy in nonsmall cell lung cancer (NSCLC). In this study, the authors compared results from EGFR mutation testing on both cytologic smears and surgical specimens and also compared the performance of platforms using 2 different technologies (pyrosequencing and real-time polymerase chain reaction) for both specimen types.


METHODS:
Specimens from 114 patients were divided into 2 subsets. The first subset had 60 paired cytology smears and surgical specimens, including 37 paired specimens from the same site and 23 paired specimens from different sites. The second subset consisted of nonpaired cytology smears and formalin-fixed, paraffin-embedded (FFPE) tissues (including 8 cell blocks), which were compared on the pyrosequencing and real-time polymerase chain reaction platforms. Laser-capture microscopy was used to enrich tumor in the FFPE specimens before DNA extraction.


RESULTS:
All cytology smears that were used in the study were adequate for analysis on both platforms. Comparison between smears and concurrent FFPE tissues from the same anatomic site had a concordance rate of 97%. The concordance rate between the pyrosequencing platform and the real-time polymerase chain reaction platform was 84% and 85% for FFPE tissues and cytology smears, respectively.


CONCLUSIONS:
The current results indicated that direct extraction and analysis of EGFR mutations from cytology smears can be performed successfully on both a pyrosequencing platform and a real-time polymerase chain reaction platform with results comparable to those achieved in matched surgical specimens. In fine-needle aspiration/endobronchial ultrasound samples with limited tissue, cytology smears can be important for molecular analysis. Cancer (Cancer Cytopathol) 2013;. © 2012 American Cancer Society.

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21262" xmlns="http://purl.org/rss/1.0/"><title>EZH2 and CD79B mutational status over time in B-cell non-Hodgkin lymphomas detected by high-throughput sequencing using minimal samples</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21262</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">EZH2 and CD79B mutational status over time in B-cell non-Hodgkin lymphomas detected by high-throughput sequencing using minimal samples</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Mauro Ajaj Saieg, William R. Geddie, Scott L. Boerner, Denis Bailey, Michael Crump, Gilda da Cunha Santos</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-01-29T14:57:24.404896-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/cncy.21262</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/cncy.21262</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21262</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<div class="section" id="cncy21262-sec-0001" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib" xmlns="http://www.w3.org/1999/xhtml"><h4>BACKGROUND</h4><div class="para"><p>Numerous genomic abnormalities in B-cell non-Hodgkin lymphomas (NHLs) have been revealed by novel high-throughput technologies, including recurrent mutations in <em>EZH2</em> (enhancer of zeste homolog 2) and <em>CD79B</em> (B cell antigen receptor complex-associated protein beta chain) genes. This study sought to determine the evolution of the mutational status of <em>EZH2</em> and <em>CD79B</em> over time in different samples from the same patient in a cohort of B-cell NHLs, through use of a customized multiplex mutation assay.</p></div></div>
<div class="section" id="cncy21262-sec-0002" xmlns="http://www.w3.org/1999/xhtml"><h4>METHODS</h4><div class="para"><p>DNA that was extracted from cytological material stored on FTA cards as well as from additional specimens, including archived frozen and formalin-fixed histological specimens, archived stained smears, and cytospin preparations, were submitted to a multiplex mutation assay specifically designed for the detection of point mutations involving <em>EZH2</em> and <em>CD79B</em>, using MassARRAY spectrometry followed by Sanger sequencing.</p></div></div>
<div class="section" id="cncy21262-sec-0003" xmlns="http://www.w3.org/1999/xhtml"><h4>RESULTS</h4><div class="para"><p>All 121 samples from 80 B-cell NHL cases were successfully analyzed. Mutations in <em>EZH2</em> (Y646) and <em>CD79B</em> (Y196) were detected in 13.2% and 8% of the samples, respectively, almost exclusively in follicular lymphomas and diffuse large B-cell lymphomas. In one-third of the positive cases, a wild type was detected in a different sample from the same patient during follow-up.</p></div></div>
<div class="section" id="cncy21262-sec-0004" xmlns="http://www.w3.org/1999/xhtml"><h4>CONCLUSIONS</h4><div class="para"><p>Testing multiple minimal tissue samples using a high-throughput multiplex platform exponentially increases tissue availability for molecular analysis and might facilitate future studies of tumor progression and the related molecular events. Mutational status of <em>EZH2</em> and <em>CD79B</em> may vary in B-cell NHL samples over time and support the concept that individualized therapy should be based on molecular findings at the time of treatment, rather than on results obtained from previous specimens. Cancer (Cancer Cytopathol) 2013. © 2013 American Cancer Society.</p></div></div>
]]></content:encoded><description>

BACKGROUND
Numerous genomic abnormalities in B-cell non-Hodgkin lymphomas (NHLs) have been revealed by novel high-throughput technologies, including recurrent mutations in EZH2 (enhancer of zeste homolog 2) and CD79B (B cell antigen receptor complex-associated protein beta chain) genes. This study sought to determine the evolution of the mutational status of EZH2 and CD79B over time in different samples from the same patient in a cohort of B-cell NHLs, through use of a customized multiplex mutation assay.


METHODS
DNA that was extracted from cytological material stored on FTA cards as well as from additional specimens, including archived frozen and formalin-fixed histological specimens, archived stained smears, and cytospin preparations, were submitted to a multiplex mutation assay specifically designed for the detection of point mutations involving EZH2 and CD79B, using MassARRAY spectrometry followed by Sanger sequencing.


RESULTS
All 121 samples from 80 B-cell NHL cases were successfully analyzed. Mutations in EZH2 (Y646) and CD79B (Y196) were detected in 13.2% and 8% of the samples, respectively, almost exclusively in follicular lymphomas and diffuse large B-cell lymphomas. In one-third of the positive cases, a wild type was detected in a different sample from the same patient during follow-up.


CONCLUSIONS
Testing multiple minimal tissue samples using a high-throughput multiplex platform exponentially increases tissue availability for molecular analysis and might facilitate future studies of tumor progression and the related molecular events. Mutational status of EZH2 and CD79B may vary in B-cell NHL samples over time and support the concept that individualized therapy should be based on molecular findings at the time of treatment, rather than on results obtained from previous specimens. Cancer (Cancer Cytopathol) 2013. © 2013 American Cancer Society.

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21318" xmlns="http://purl.org/rss/1.0/"><title>Weighty talks about wise choices</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21318</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Weighty talks about wise choices</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Bryn Nelson</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-06-13T09:37:16.811719-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/cncy.21318</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/cncy.21318</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21318</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">CytoSource</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">277</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">278</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[]]></content:encoded><description/></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21270" xmlns="http://purl.org/rss/1.0/"><title>The marriage of Cytology and Cytogenetics</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21270</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">The marriage of Cytology and Cytogenetics</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Paola Dal Cin, Xiaohua Qian, Edmund S. Cibas</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-01-03T10:01:00.271412-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/cncy.21270</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/cncy.21270</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21270</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Commentary</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">279</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">290</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<div class="para" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib" xmlns="http://www.w3.org/1999/xhtml"><p>The past 20 years have witnessed extraordinary advances in the field of cytogenetics, with the discovery that a multitude of neoplasms is characterized by identifiable chromosomal changes. The ability of Cytogenetics to aid in the identification and precise classification of a variety of neoplasms has not gone unnoticed by Cytology. In particular, Cytology has recognized Cytogenetics as a welcome companion in the evaluation of soft tissue tumors, lymphomas, renal and urothelial tumors, and mesothelioma. This relationship requires a good understanding of the proper handling of specimens for optimal evaluation by Cytogenetics. The marriage of Cytology and Cytogenetics will likely grow stronger as more solid tumors (eg, salivary gland neoplasms) are discovered that harbor characteristic chromosomal abnormalities. Cancer (Cancer Cytopathol) 2013;121:279–90. © 2013 American Cancer Society.</p></div>
]]></content:encoded><description>
The past 20 years have witnessed extraordinary advances in the field of cytogenetics, with the discovery that a multitude of neoplasms is characterized by identifiable chromosomal changes. The ability of Cytogenetics to aid in the identification and precise classification of a variety of neoplasms has not gone unnoticed by Cytology. In particular, Cytology has recognized Cytogenetics as a welcome companion in the evaluation of soft tissue tumors, lymphomas, renal and urothelial tumors, and mesothelioma. This relationship requires a good understanding of the proper handling of specimens for optimal evaluation by Cytogenetics. The marriage of Cytology and Cytogenetics will likely grow stronger as more solid tumors (eg, salivary gland neoplasms) are discovered that harbor characteristic chromosomal abnormalities. Cancer (Cancer Cytopathol) 2013;121:279–90. © 2013 American Cancer Society.
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21258" xmlns="http://purl.org/rss/1.0/"><title>BRAF (V600E) mutation analysis on liquid-based cytology-processed aspiration biopsies predicts bilaterality and lymph node involvement in papillary thyroid microcarcinoma</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21258</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">BRAF (V600E) mutation analysis on liquid-based cytology-processed aspiration biopsies predicts bilaterality and lymph node involvement in papillary thyroid microcarcinoma</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Esther Diana Rossi, Maurizio Martini, Sara Capodimonti, Celestino Pio Lombardi, Alfredo Pontecorvi, Valerio Gaetano Vellone, Gian Franco Zannoni, Luigi Maria Larocca, Guido Fadda</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-11-28T10:09:59.091301-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/cncy.21258</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/cncy.21258</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21258</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">291</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">297</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<div class="section" id="cncy21258-sec-0001" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib" xmlns="http://www.w3.org/1999/xhtml"><h4>BACKGROUND</h4><div class="para"><p>Activating mutations in the valine-to-glutamic acid substitution at position 600 of the v-raf murine sarcoma viral oncogene homolog B1 (<em>BRAF-1</em>) gene are detected frequently in patients with papillary thyroid carcinoma (PTC). These mutations have been identified in approximately 29% to 69% of PTCs and in &gt;80% of PTCs of the tall cell variant, whereas they have not been detected in benign lesions or in the majority of those (80%) with the follicular variant of PTC. The objective of the current study was to evaluate the role of liquid-based cytology (LBC) for the detection of <em>BRAF</em> mutations in the outcome of patients who have thyroid PTC measuring ≤1 cm and, hence, in guiding their clinical and surgical management.</p></div></div>
<div class="section" id="cncy21258-sec-0002" xmlns="http://www.w3.org/1999/xhtml"><h4>METHODS</h4><div class="para"><p>From October 2010 through June 2011, 230 consecutive cases were diagnosed as positive for malignancy on fine-needle aspiration cytology processed by LBC. Of these, 73 PTCs ≤1 cm underwent <em>BRAF</em> mutational analysis. The aspirated material was processed using an LBC technique. After DNA extraction of the residual material, <em>BRAF</em> mutation analysis was performed using a direct sequencing method.</p></div></div>
<div class="section" id="cncy21258-sec-0003" xmlns="http://www.w3.org/1999/xhtml"><h4>RESULTS</h4><div class="para"><p>Fifty of 73 patients (68.5%) underwent surgery, and 34 of those patients (68%) had tumors that expressed a <em>BRAF</em> mutation (31 PTCs, including 11 tall cell variants and 3 follicular-variant PTCs). A significant association between <em>BRAF</em> mutation and bilaterality of cancer was observed (odds ratio, 0.077; <em>P</em> = .0007). <em>BRAF</em> mutation was associated significantly with lymph node involvement (odds ratio, 19; <em>P</em> = .0007) but not with extracapsular infiltration (odds ratio, 0.298; <em>P</em> = .179).</p></div></div>
<div class="section" id="cncy21258-sec-0004" xmlns="http://www.w3.org/1999/xhtml"><h4>CONCLUSIONS</h4><div class="para"><p>The current results indicated that <em>BRAF</em> gene mutations can be identified successfully on LBC material and using other cytologic methods with high reproducibility, feasibility, and informative results. The presence of a <em>BRAF</em> mutation may preoperatively predict the behavior of microscopic PTC, suggesting a more aggressive surgical approach. Cancer (Cancer Cytopathol) 2013;121:291–7. © 2012 American Cancer Society.</p></div></div>
]]></content:encoded><description>

BACKGROUND
Activating mutations in the valine-to-glutamic acid substitution at position 600 of the v-raf murine sarcoma viral oncogene homolog B1 (BRAF-1) gene are detected frequently in patients with papillary thyroid carcinoma (PTC). These mutations have been identified in approximately 29% to 69% of PTCs and in &gt;80% of PTCs of the tall cell variant, whereas they have not been detected in benign lesions or in the majority of those (80%) with the follicular variant of PTC. The objective of the current study was to evaluate the role of liquid-based cytology (LBC) for the detection of BRAF mutations in the outcome of patients who have thyroid PTC measuring ≤1 cm and, hence, in guiding their clinical and surgical management.


METHODS
From October 2010 through June 2011, 230 consecutive cases were diagnosed as positive for malignancy on fine-needle aspiration cytology processed by LBC. Of these, 73 PTCs ≤1 cm underwent BRAF mutational analysis. The aspirated material was processed using an LBC technique. After DNA extraction of the residual material, BRAF mutation analysis was performed using a direct sequencing method.


RESULTS
Fifty of 73 patients (68.5%) underwent surgery, and 34 of those patients (68%) had tumors that expressed a BRAF mutation (31 PTCs, including 11 tall cell variants and 3 follicular-variant PTCs). A significant association between BRAF mutation and bilaterality of cancer was observed (odds ratio, 0.077; P = .0007). BRAF mutation was associated significantly with lymph node involvement (odds ratio, 19; P = .0007) but not with extracapsular infiltration (odds ratio, 0.298; P = .179).


CONCLUSIONS
The current results indicated that BRAF gene mutations can be identified successfully on LBC material and using other cytologic methods with high reproducibility, feasibility, and informative results. The presence of a BRAF mutation may preoperatively predict the behavior of microscopic PTC, suggesting a more aggressive surgical approach. Cancer (Cancer Cytopathol) 2013;121:291–7. © 2012 American Cancer Society.

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21259" xmlns="http://purl.org/rss/1.0/"><title>Cercariform cells: Another cytologic feature distinguishing solid pseudopapillary neoplasms from pancreatic endocrine neoplasms and acinar cell carcinomas in endoscopic ultrasound-guided fine-needle aspirates</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21259</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Cercariform cells: Another cytologic feature distinguishing solid pseudopapillary neoplasms from pancreatic endocrine neoplasms and acinar cell carcinomas in endoscopic ultrasound-guided fine-needle aspirates</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Arbaz Samad, Akeesha A. Shah, Edward B. Stelow, Mariam Alsharif, Stuart E. H. Cameron, Stefan E. Pambuccian</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-12-05T10:17:12.635959-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/cncy.21259</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/cncy.21259</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21259</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">298</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">310</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<div class="section" id="cncy21259-sec-0001" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib" xmlns="http://www.w3.org/1999/xhtml"><h4>BACKGROUND</h4><div class="para"><p>Solid pseudopapillary neoplasm (SPPN) is a rare tumor of unknown origin that occurs predominantly in the body or tail of the pancreas in young women. The authors recently identified cercariform (Greek: tailed) cells, similar to those described in urothelial carcinomas, as a consistent cytologic feature in ultrasound-guided fine-needle aspiration (EUS-FNA) samples from SPPNs. The objective of the current multi-institutional study was to define the value of these cells in the differential diagnosis of SPPN with other neoplasms characterized cytologically by the presence of monotonous, uniform cells in pancreatic aspirates: pancreatic neuroendocrine tumors (Pan-NETs) and acinar cell carcinomas (ACCs).</p></div></div>
<div class="section" id="cncy21259-sec-0002" xmlns="http://www.w3.org/1999/xhtml"><h4>METHODS</h4><div class="para"><p>The files of 4 academic hospitals were searched for SPPNs, Pan-NETs, and ACCs that were diagnosed by EUS-FNA. The slides were reviewed, and several cytologic features were recorded semiquantitatively to identify discriminating features between SPPNs, Pan-NETs, and ACCs.</p></div></div>
<div class="section" id="cncy21259-sec-0003" xmlns="http://www.w3.org/1999/xhtml"><h4>RESULTS</h4><div class="para"><p>From the analysis of 18 SPPNs, 4 ACCs, and 20 Pan-NETs, the following cytologic features were identified as common to all 3 neoplasms: single cells and rosettes/acinar cell groups, round-to-plasmacytoid cells, pale-to-granular cytoplasm, fine vacuoles, and binucleated cells. Papillary structures, cercariform cells, large cytoplasmic vacuoles, reniform nuclei, hyaline globules/magenta-colored material, and degenerative features (cholesterol crystals, calcifications, foam cells, or giant cells) were significantly more common in SPPNs. Prominent nuclear grooves were encountered in only 4 of 18 SPPNs.</p></div></div>
<div class="section" id="cncy21259-sec-0004" xmlns="http://www.w3.org/1999/xhtml"><h4>CONCLUSIONS</h4><div class="para"><p>The current results indicated that the presence of cercariform cells is another useful clue for the cytologic diagnosis of SPPN in challenging cases. Cancer (Cancer Cytopathol) 2013;121:298–310. © 2012 American Cancer Society.</p></div></div>
]]></content:encoded><description>

BACKGROUND
Solid pseudopapillary neoplasm (SPPN) is a rare tumor of unknown origin that occurs predominantly in the body or tail of the pancreas in young women. The authors recently identified cercariform (Greek: tailed) cells, similar to those described in urothelial carcinomas, as a consistent cytologic feature in ultrasound-guided fine-needle aspiration (EUS-FNA) samples from SPPNs. The objective of the current multi-institutional study was to define the value of these cells in the differential diagnosis of SPPN with other neoplasms characterized cytologically by the presence of monotonous, uniform cells in pancreatic aspirates: pancreatic neuroendocrine tumors (Pan-NETs) and acinar cell carcinomas (ACCs).


METHODS
The files of 4 academic hospitals were searched for SPPNs, Pan-NETs, and ACCs that were diagnosed by EUS-FNA. The slides were reviewed, and several cytologic features were recorded semiquantitatively to identify discriminating features between SPPNs, Pan-NETs, and ACCs.


RESULTS
From the analysis of 18 SPPNs, 4 ACCs, and 20 Pan-NETs, the following cytologic features were identified as common to all 3 neoplasms: single cells and rosettes/acinar cell groups, round-to-plasmacytoid cells, pale-to-granular cytoplasm, fine vacuoles, and binucleated cells. Papillary structures, cercariform cells, large cytoplasmic vacuoles, reniform nuclei, hyaline globules/magenta-colored material, and degenerative features (cholesterol crystals, calcifications, foam cells, or giant cells) were significantly more common in SPPNs. Prominent nuclear grooves were encountered in only 4 of 18 SPPNs.


CONCLUSIONS
The current results indicated that the presence of cercariform cells is another useful clue for the cytologic diagnosis of SPPN in challenging cases. Cancer (Cancer Cytopathol) 2013;121:298–310. © 2012 American Cancer Society.

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21260" xmlns="http://purl.org/rss/1.0/"><title>High concordance of EGFR mutation status between histologic and corresponding cytologic specimens of lung adenocarcinomas</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21260</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">High concordance of EGFR mutation status between histologic and corresponding cytologic specimens of lung adenocarcinomas</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Ping-Li Sun, Yan Jin, Hyojin Kim, Choon-Taek Lee, Sanghoon Jheon, Jin-Haeng Chung</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-12-05T10:16:33.682494-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/cncy.21260</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/cncy.21260</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21260</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">311</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">319</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<div class="section" id="cncy21260-sec-0001" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib" xmlns="http://www.w3.org/1999/xhtml"><h4>BACKGROUND</h4><div class="para"><p>Activating mutations in the epidermal growth factor receptor (<em>EGFR</em>) in non–small cell lung carcinoma (NSCLC) are associated significantly with responsiveness to EGFR tyrosine kinase inhibitors. The objective of this study was to investigate the suitability of cytologic specimens for assessing <em>EGFR</em> mutations in lung adenocarcinomas.</p></div></div>
<div class="section" id="cncy21260-sec-0002" xmlns="http://www.w3.org/1999/xhtml"><h4>METHODS</h4><div class="para"><p>Sixty paired histologic and cytologic specimens of lung adenocarcinoma were collected. Exons 18 through 21 of the <em>EGFR</em> gene were amplified using polymerase chain reaction, and the mutation status of each sample was analyzed by pyrosequencing. A comparison of <em>EGFR</em> mutation status between histologic specimens and cytologic specimens was performed.</p></div></div>
<div class="section" id="cncy21260-sec-0003" xmlns="http://www.w3.org/1999/xhtml"><h4>RESULTS</h4><div class="para"><p>The overall <em>EGFR</em> mutation concordance rate between histologic specimens and corresponding cytologic specimens was 91.7%. No significant difference was observed in the concordance rate between cytologic specimens from primary lesions and specimens from metastatic lesions (<em>P</em> = .63). The following parameters were correlated with the most reliable <em>EGFR</em> mutation results using the pyrosequencing method (100% concordance with the corresponding histologic specimens) in cytologic samples: a DNA concentration &gt;25 ng/μL, content of &gt;30 tumor cells, or a tumor percentage &gt;30%.</p></div></div>
<div class="section" id="cncy21260-sec-0004" xmlns="http://www.w3.org/1999/xhtml"><h4>CONCLUSIONS</h4><div class="para"><p>In this study, routinely prepared cytologic specimens were reliable sources for assessing <em>EGFR</em> mutation status. The authors concluded that cytologic specimens from metastatic lesions and primary tumors are suitable for the successful assessment of <em>EGFR</em> mutation status. Cancer (Cancer Cytopathol) 2013;121:311–9. © 2012 American Cancer Society.</p></div></div>
]]></content:encoded><description>

BACKGROUND
Activating mutations in the epidermal growth factor receptor (EGFR) in non–small cell lung carcinoma (NSCLC) are associated significantly with responsiveness to EGFR tyrosine kinase inhibitors. The objective of this study was to investigate the suitability of cytologic specimens for assessing EGFR mutations in lung adenocarcinomas.


METHODS
Sixty paired histologic and cytologic specimens of lung adenocarcinoma were collected. Exons 18 through 21 of the EGFR gene were amplified using polymerase chain reaction, and the mutation status of each sample was analyzed by pyrosequencing. A comparison of EGFR mutation status between histologic specimens and cytologic specimens was performed.


RESULTS
The overall EGFR mutation concordance rate between histologic specimens and corresponding cytologic specimens was 91.7%. No significant difference was observed in the concordance rate between cytologic specimens from primary lesions and specimens from metastatic lesions (P = .63). The following parameters were correlated with the most reliable EGFR mutation results using the pyrosequencing method (100% concordance with the corresponding histologic specimens) in cytologic samples: a DNA concentration &gt;25 ng/μL, content of &gt;30 tumor cells, or a tumor percentage &gt;30%.


CONCLUSIONS
In this study, routinely prepared cytologic specimens were reliable sources for assessing EGFR mutation status. The authors concluded that cytologic specimens from metastatic lesions and primary tumors are suitable for the successful assessment of EGFR mutation status. Cancer (Cancer Cytopathol) 2013;121:311–9. © 2012 American Cancer Society.

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21264" xmlns="http://purl.org/rss/1.0/"><title>ProEx C as an adjunct marker to improve cytological detection of urothelial carcinoma in urinary specimens</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21264</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">ProEx C as an adjunct marker to improve cytological detection of urothelial carcinoma in urinary specimens</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Neda A. Moatamed, Jian-Yu Rao, Serge Alexanian, Melissa Cobarrubias, Mary Levin, David Lu, Sophia K. Apple</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-01-30T08:58:19.287131-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/cncy.21264</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/cncy.21264</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21264</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">320</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">328</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<div class="section" id="cncy21264-sec-0001" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib" xmlns="http://www.w3.org/1999/xhtml"><h4>BACKGROUND</h4><div class="para"><p>ProEx C is an antibody cocktail targeting the expression of topoisomerase IIα and minichromosome maintenance protein-2. ProEx C staining is being used to assist in diagnoses of the gynecological specimens. This study was designed to determine the utility of ProEx C in urine cytology samples for improving the detection of urothelial carcinomas where a significant number of urine cytology specimens are diagnosed as “atypia.”</p></div></div>
<div class="section" id="cncy21264-sec-0002" xmlns="http://www.w3.org/1999/xhtml"><h4>METHODS</h4><div class="para"><p>Sixty urinary specimens (12 negative, 13 positive, and 35 atypical cases) were stained with ProEx C, and ProEx C results were recorded as positive when nuclear staining was only seen in at least one morphologically atypical urothelial cell.</p></div></div>
<div class="section" id="cncy21264-sec-0003" xmlns="http://www.w3.org/1999/xhtml"><h4>RESULTS</h4><div class="para"><p>All 12 benign cytology samples showed negative staining with ProEx C. Twelve of 13 cases that had a malignant cytologic diagnosis showed a positive nuclear staining of the malignant cells. Eighteen of 35 cases with atypical cytologic diagnoses showed positive nuclear staining. Of the 35 cases with “atypia,” 17 had a malignant histopathologic follow-up. In this study, ProEx C stain had an overall sensitivity of 78.4%, specificity of 95.7%%, positive predictive value of 96.7%, and negative predictive value of 73.3% for the detection of urothelial carcinoma.</p></div></div>
<div class="section" id="cncy21264-sec-0004" xmlns="http://www.w3.org/1999/xhtml"><h4>CONCLUSIONS</h4><div class="para"><p>ProEx C stain is a useful adjunct test to urine cytologic analysis, even in specimens with limited cellularity. In urinary smears, this test is most useful in stratification of the “atypical” diagnoses into benign and malignant subsets. To the authors' knowledge, this is the first study of ProEx C application in urine cytology as an adjunct marker for detection of urothelial carcinoma. Cancer (Cancer Cytopathol) 2013;121:320–8. © 2013 American Cancer Society.</p></div></div>
]]></content:encoded><description>

BACKGROUND
ProEx C is an antibody cocktail targeting the expression of topoisomerase IIα and minichromosome maintenance protein-2. ProEx C staining is being used to assist in diagnoses of the gynecological specimens. This study was designed to determine the utility of ProEx C in urine cytology samples for improving the detection of urothelial carcinomas where a significant number of urine cytology specimens are diagnosed as “atypia.”


METHODS
Sixty urinary specimens (12 negative, 13 positive, and 35 atypical cases) were stained with ProEx C, and ProEx C results were recorded as positive when nuclear staining was only seen in at least one morphologically atypical urothelial cell.


RESULTS
All 12 benign cytology samples showed negative staining with ProEx C. Twelve of 13 cases that had a malignant cytologic diagnosis showed a positive nuclear staining of the malignant cells. Eighteen of 35 cases with atypical cytologic diagnoses showed positive nuclear staining. Of the 35 cases with “atypia,” 17 had a malignant histopathologic follow-up. In this study, ProEx C stain had an overall sensitivity of 78.4%, specificity of 95.7%%, positive predictive value of 96.7%, and negative predictive value of 73.3% for the detection of urothelial carcinoma.


CONCLUSIONS
ProEx C stain is a useful adjunct test to urine cytologic analysis, even in specimens with limited cellularity. In urinary smears, this test is most useful in stratification of the “atypical” diagnoses into benign and malignant subsets. To the authors' knowledge, this is the first study of ProEx C application in urine cytology as an adjunct marker for detection of urothelial carcinoma. Cancer (Cancer Cytopathol) 2013;121:320–8. © 2013 American Cancer Society.

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21263" xmlns="http://purl.org/rss/1.0/"><title>To what extent does nonanalytic reasoning contribute to visual learning in cytopathology?</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21263</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">To what extent does nonanalytic reasoning contribute to visual learning in cytopathology?</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Andrew Evered, Darren Walker, Andrew A. Watt, Nick Perham</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-02-06T10:19:11.807107-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/cncy.21263</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/cncy.21263</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fcncy.21263</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">329</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">338</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<div class="section" id="cncy21263-sec-0001" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib" xmlns="http://www.w3.org/1999/xhtml"><h4>BACKGROUND</h4><div class="para"><p>Acquisition of visual interpretation skills in cytopathology may involve 2 strategies. Analytic strategies require trainees to base their interpretive decisions on carefully considered and often exhaustive cytomorphologic feature lists, a process that can be time-consuming and inefficient. In contrast, nonanalytic pattern recognition strategies are rarely encouraged during training, even though this approach is characteristic of expert diagnostic behavior. This study evaluated the potential role of nonanalytic learning in cytopathology as an efficient alternative to analytic training.</p></div></div>
<div class="section" id="cncy21263-sec-0002" xmlns="http://www.w3.org/1999/xhtml"><h4>METHODS</h4><div class="para"><p>Forty-nine cytology novice participants undertook an initial image interpretation test to obtain baseline diagnostic accuracy (test 1). Twenty-four participants subsequently received training in basic cervical cytomorphology and were given a list of cell features for future reference (the “analytic” group). The remaining 25 participants were simply shown 20 nonannotated paired images of normal and abnormal cervical cells (the “nonanalytic” group). Following a practice phase, both groups were retested (test 2). Prior to a final test (test 3), participants in both groups were instructed to adopt a combined analytic/nonanalytic diagnostic strategy. Diagnostic accuracy and response times were measured in each test.</p></div></div>
<div class="section" id="cncy21263-sec-0003" xmlns="http://www.w3.org/1999/xhtml"><h4>RESULTS</h4><div class="para"><p>Diagnostic accuracy in both groups improved significantly between tests 1 and 2 (<em>P</em>&lt;.001) but decreased between tests 2 and 3 (<em>P</em>&lt;.05). Speed of response to test images was generally faster under nonanalytic than under analytic conditions.</p></div></div>
<div class="section" id="cncy21263-sec-0004" xmlns="http://www.w3.org/1999/xhtml"><h4>CONCLUSIONS</h4><div class="para"><p>Nonanalytic reasoning in cytopathology image interpretation can be as accurate as traditional feature-based reasoning. Encouraging trainees to adopt pattern recognition strategies may help to expedite the acquisition of visual interpretation skills in cytopathology training programs, yet combining analytic and nonanalytic reasoning do not appear to be effective. Cancer (Cancer Cytopathol) 2013;121:329–38. © 2013 American Cancer Society.</p></div></div>
]]></content:encoded><description>

BACKGROUND
Acquisition of visual interpretation skills in cytopathology may involve 2 strategies. Analytic strategies require trainees to base their interpretive decisions on carefully considered and often exhaustive cytomorphologic feature lists, a process that can be time-consuming and inefficient. In contrast, nonanalytic pattern recognition strategies are rarely encouraged during training, even though this approach is characteristic of expert diagnostic behavior. This study evaluated the potential role of nonanalytic learning in cytopathology as an efficient alternative to analytic training.


METHODS
Forty-nine cytology novice participants undertook an initial image interpretation test to obtain baseline diagnostic accuracy (test 1). Twenty-four participants subsequently received training in basic cervical cytomorphology and were given a list of cell features for future reference (the “analytic” group). The remaining 25 participants were simply shown 20 nonannotated paired images of normal and abnormal cervical cells (the “nonanalytic” group). Following a practice phase, both groups were retested (test 2). Prior to a final test (test 3), participants in both groups were instructed to adopt a combined analytic/nonanalytic diagnostic strategy. Diagnostic accuracy and response times were measured in each test.


RESULTS
Diagnostic accuracy in both groups improved significantly between tests 1 and 2 (P&lt;.001) but decreased between tests 2 and 3 (P&lt;.05). Speed of response to test images was generally faster under nonanalytic than under analytic conditions.


CONCLUSIONS
Nonanalytic reasoning in cytopathology image interpretation can be as accurate as traditional feature-based reasoning. Encouraging trainees to adopt pattern recognition strategies may help to expedite the acquisition of visual interpretation skills in cytopathology training programs, yet combining analytic and nonanalytic reasoning do not appear to be effective. Cancer (Cancer Cytopathol) 2013;121:329–38. © 2013 American Cancer Society.

</description></item></rdf:RDF>